^
9h
Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), is used as second-line therapy for sorafenib- or sunitinib-refractory metastatic RCC. Moreover, the forced expression of GPX4 abrogated ferroptosis induced by the combined treatment of Everolimus and RSL3/Erastin. Taken together, these results demonstrated that Everolimus in combination with RSL3/Erastin is a promising therapeutic option for RCC treatment and it may also help to overcome the limitation in clinical applicability of Everolimus.
Journal
|
GPX4 (Glutathione Peroxidase 4) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
|
GPX4 expression
|
Nexavar (sorafenib) • Sutent (sunitinib) • everolimus • erastin • RSL3
1d
Here we investigated the effects on tumor growth and on the tumor microenvironment of three different direct and indirect HIF-α inhibitors, namely the HIF-2α-specific inhibitor PT2399, the dual HIF-1α/HIF-2α inhibitor Acriflavine, and the S1P signaling pathway inhibitor FTY720, in the autochthonous Vhl/Trp53/Rb1 mutant ccRCC mouse model and validated these findings in human ccRCC cell culture models. We also identify that HIF-2α inhibition strongly suppresses T cell activation in ccRCC. These findings suggest prioritization of sphingosine pathway inhibitors for clinical testing in ccRCC patients and also suggest that HIF-2α inhibitors may inhibit anti-tumor immunity and might therefore be contraindicated for combination therapies with immune checkpoint inhibitors.
Journal • IO biomarker
|
RB1 (RB Transcriptional Corepressor 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • EPAS1 (Endothelial PAS domain protein 1)
|
RB1 mutation
|
fingolimod • PT2399
1d
Further functional studies demonstrated that that the inhibition effect of NNT-AS1 knockdown on ccRCC carcinogenesis could be partially reversed by overexpression of YBX-1, suggesting that NNT-AS1 promotes ccRCC progression through the miR-137/YBX-1 pathway. In summary, those findings indicate that NNT-AS1 promotes ccRCC progression via the miR-137/YBX-1 pathway, which may provide a promising therapeutic target for renal cell carcinoma.
Journal
|
YBX1 (Y-Box Binding Protein 1)
2d
We then externally validate our results and devise a workflow with optimal biomarker cut-offs for discriminating the LAG-3, TIM-3, and TIGIT tumour profiles. The discrimination of LAG-3, TIM-3, and TIGIT profiles in tumours may have a broad impact on investigations of immunotherapy responses after targeting a new series of IRs.
Journal • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
2d
CD44 is involved in sunitinib resistance and may be a promising marker for sunitinib treatment in mRCC.
Journal • PD(L)-1 Biomarker
|
CD44
|
CD44 expression • CD44 positive
|
Sutent (sunitinib) • Bavencio (avelumab) • Inlyta (axitinib)
3d
A FLCN gene mutation should be excluded in those with recurrent PTX. Genetic testing should be considered as well as appropriate cancer screening with renal ultrasound and colonoscopy given its association with BHD.
Clinical
|
FLCN (Folliculin)
|
FLCN mutation
3d
This is the first reported case of BHDS with simultaneous findings of a pericardial cyst. This may represent a possible phenotypic manifestation of this syndrome that has not yet been described in literature.
Clinical
|
FLCN (Folliculin)
|
FLCN mutation
3d
BHDS is an extremely rare autosomal dominant disorder that should be suspected in patients with a personal and family history of pulmonary cysts, spontaneous pneumothoraces, skin lesions, and renal tumors.
Clinical
|
FLCN (Folliculin)
|
FLCN mutation
3d
Dexamethasone, vancomycin and piperacillin-tazobactam were initiated, and one dose of Remdesivir was given after an unremarkable liver panel...The patient was treated with N-acetylcysteine, methylprednisolone, lactulose and rifaximin...It has been shown to cause severe liver injury only when used in combination with amiodarone, due to the latter's role as a moderate inhibitor of CYP3A4 and p-glycoprotein (3)... Understanding SARS-CoV-2's effects on a hepatocellular level may allow for anticipatory monitoring and prevention of liver damage from this virus. For those more severely affected, better treatments would help avoid the difficult course of emergency liver transplantation and resultant need for lifelong immunosuppression.
Clinical
|
IL6 (Interleukin 6) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
|
dexamethasone • Xifaxan (rifaximin) • amiodarone • lactulose • piperacillin sodium/tazobactam sodium • remdesivir • vancomycin
3d
This case demonstrates that a high suspicion level and thorough management can achieve reasonable levels of diagnosis and high survival rates even when two rare entities are bound in the same case.
BRAF (B-raf proto-oncogene)
|
BRAF mutation
3d
Enrollment open
|
CRP (C-reactive protein)
|
Bavencio (avelumab) • Inlyta (axitinib)
3d
Clinical • New P1 trial • Combination therapy
|
VHL (von Hippel-Lindau tumor suppressor) • EPAS1 (Endothelial PAS domain protein 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2) • SDHD (Succinate Dehydrogenase Complex Subunit D)
|
VHL mutation • SDHB mutation
|
everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)
3d
Functional recovery experiment confirmed that Wnt/β-catenin pathway was essential for ccRCC progression and metastasis. Developing selective drugs targeting CENPA may be a promising direction for cancer treatment.
Journal
|
CENPA (Centromere protein A)
3d
Among patients treated with nivolumab (n = 181), overall survival (OS) was significantly higher in the PARP1-low group than in the PARP1-high group (p = 0.006), and PARP1 status was significantly associated with OS (hazard ratio [HR] 1.7; p = 0.007). By contrast, for patients treated with everolimus (n = 130) there was no significant difference by PARP1 status for progression-free survival (PFS; p = 0.9) or OS (p = 0.38)...PATIENT SUMMARY: Immune checkpoint inhibitors (ICIs) are key agents in the treatment of multiple cancers. We found that expression of the PARP1 protein was associated with survival after ICI treatment and with the response to ICI treatment in patients with clear cell kidney cancer who have a mutation of the PBRM1 gene.
Clinical • Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PBRM1 (Polybromo 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
PBRM1 mutation
|
Opdivo (nivolumab) • everolimus
3d
Somatic sequencing performed on their respective tumors could help discern the etiology of the component tumors, highlighting the role of somatic evaluation in these cases. Paired examination of somatic and germline findings provided a more complete landscape of genome alterations in cancer development.
Journal
|
VHL (von Hippel-Lindau tumor suppressor)
3d
Our study was performing a four-microRNA panel in serum for screening enal cell carcinoma. The four-miRNA panel (miR-21-5p, miR-150-5p, miR-145-5p and miR-146a-5p) may be perform as a biomarker without invasiveness for RCC screening.
Journal
|
MIR21 (MicroRNA 21) • MIR146A (MicroRNA 146a) • MIR17 (MicroRNA 17) • MIR150 (MicroRNA 150) • MIR20A (MicroRNA 20a)
3d
The cells are surrounded by an abundant smooth muscle stroma with focally osseous metaplasia. The tumor was positive for carbonic anhydrase IX, cytokeratin 7, cytokeratin 20, and CD10, and negative for TFE3. This emerging entity is highly correlated to tuberous sclerosis complex, which justifies a screening for the syndrome when this diagnosis is made.
Clinical • Journal
|
TSC2 (TSC complex subunit 2) • TFE3 • CA9 (Carbonic anhydrase 9) • KRT20 (Keratin 20) • MME (Membrane metallo-endopeptidase)
|
TSC2 mutation
3d
The power of this prognostic signature was superior to other signatures reported in previous studies. We developed and successfully validated a novel ARG signature for predicting prognosis of subtype 1 ccRCC, which was superior to several previous signatures.
Clinical • Journal • IO biomarker
|
TIMP1 (Tissue inhibitor of metalloproteinases 1)
3d
PTP4A3 expression correlated genes involved in B cells, monocytes, M1 macrophages, Th2 and Treg cells in papillary renal cell carcinoma. These results suggest PTP4A3 as a prognostic factor with a role in regulating immune cell infiltration in papillary renal cell carcinoma.
Journal
|
CD8 (cluster of differentiation 8) • TGFB1 (Transforming Growth Factor Beta 1) • CD4 (CD4 Molecule) • PTP4A3 (Protein Tyrosine Phosphatase 4A3)
3d
The expression of HOXC11 and HOTAIR was found to be associated with poor prognosis in colon adenocarcinoma and kidney renal clear cell carcinoma. Furthermore, HOXC11 was found to positively regulate HOTAIR by RNA duplex formation and promoted the proliferation and invasion of colon adenocarcinoma cells.
Journal
|
HOTAIR (HOX Transcript Antisense RNA)
3d
Furthermore, they activated the expressions of PPARs, Nrf2, and IL-4 in addition to downregulation of apoptotic proteins p53 and caspase-3 and upregulation of antiapoptotic mediator Bcl-2. The obtained data supply potent proof for the efficacy of STE, Sm, and Sb to counteract renal carcinogenesis via alteration of varied molecular pathways.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • CASP3 (Caspase 3) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • RELA (RELA Proto-Oncogene) • IL4 (Interleukin 4)
|
Legalon (silibinin)
3d
Thus, the established scores were successfully verified by the validated cohort, and the nomogram was constructed and successfully validated. The identification of the histone acetylation-related subtypes and score in our study may help reveal the potential relation between histone acetylation and immunity and provide novel insights for the development of individualized therapy for ccRCC.
Journal • Tumor Mutational Burden • Epigenetic controller
|
TMB (Tumor Mutational Burden) • HDAC5 (Histone Deacetylase 5) • SIRT1 (Sirtuin 1)
3d
Enrichment analysis showed that TLR4 was highly expressed in the chemokine signaling pathway and the cell adhesion molecule and cytokine receptor interaction pathway. In summary, the expression of TLR4 is linked to the prognosis of KIRC, SKCM, STAD, TGCT, and UCEC patients and the level of immune infiltration of CD4, CD8 T cells, macrophages, neutrophils, and dendritic cells.
Journal • Tumor Mutational Burden • IO biomarker • Pan tumor
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TLR4 (Toll Like Receptor 4) • CD4 (CD4 Molecule) • DNMT3B (DNA Methyltransferase 3 Beta) • ICOS (Inducible T Cell Costimulator)
3d
Moreover, knockdown of ABCD1 in ccRCC cells decreased cancer cell migration and spheroid formation, and upregulation of ABCD1 acts as an adverse prognosis factor of kidney cancer patients. In summary, our study identifies that METTL3 promotes ccRCC progression through mA modification-mediated translation of ABCD1, providing an epitranscriptional insight into the molecular mechanism in kidney cancer.
Journal
|
METTL3 (Methyltransferase Like 3)
3d
In addition, qRT-PCR experiments confirmed our results in renal cell lines and tissue samples. According to the seven selected regulatory factors of mC RNA methylation, a risk signature associated with mC methylation that can independently predict prognosis in patients with ccRCC was developed and further verified the predictive efficiency.
Journal
|
CD8 (cluster of differentiation 8) • TET2 (Tet Methylcytosine Dioxygenase 2) • DNMT3B (DNA Methyltransferase 3 Beta)
3d
Journal
|
MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • G3BP1 (G3BP Stress Granule Assembly Factor 1)
|
Sutent (sunitinib)
4d
Secondary objectives are objective response rate and duration of response per RECIST v1.1 by blinded independent central review and safety. The study is enrolling or planning to enroll at sites in Asia, Australia, Europe, North America, and South America.
Clinical • P3 data
|
EPAS1 (Endothelial PAS domain protein 1)
|
lenvatinib • Cabometyx (cabozantinib tablet) • Welireg (belzutifan)
4d
Conclusions The TME of pRCC appears distinct from ccRCC, with a lower proportion of macrophages and MDSCs. Macrophages in the TME may be associated with clinical benefit among patients with pRCC receiving MET inhibitors.
PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD33 (CD33 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3)
4d
Sarcomatoid ccRCC appears to be less responsive. DECT results suggest that SLM may increase vascularization in tumor tissue while having no impact on normal tissue, leading to increase axi delivery to the tumor.
Clinical
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
Inlyta (axitinib) • selenomethionine (SLM)
4d
Primary end points will be assessed in arm A compared with arm C and in arm B compared with arm C for patients with IMDC intermediate/poor status and in all patients regardless of IMDC status. Secondary end points are objective response rate, duration of response, patient-reported outcomes, and safety.
Clinical • P3 data
|
EPAS1 (Endothelial PAS domain protein 1)
|
Keytruda (pembrolizumab) • lenvatinib • Welireg (belzutifan) • quavonlimab/pembrolizumab (MK-1308A)
4d
We found that these tumors are sensitive to the VEGFR inhibitor axitinib, a commonly used treatment for human ccRCC...The immediate next steps for this work include testing the necessity of the PBRM1, KEAP1 and TSC1 guides in causing renal tumor development, and testing alternate Cre recombinase promoters to assess if gene knockouts in specific kidney cell types (i.e. distal vs proximal tubule cells) will alter tumor histology or development. Conclusions We have developed an immunocompetent mouse model of VHL-null ccRCC.
Preclinical
|
KEAP1 (Kelch Like ECH Associated Protein 1) • PBRM1 (Polybromo 1) • TSC1 (TSC complex subunit 1) • EPAS1 (Endothelial PAS domain protein 1) • PAX8 (Paired box 8)
|
CDH1 expression
|
Inlyta (axitinib)
4d
Median time to response was shorter and responses were more durable with NIVO+CABO versus SUN. No new safety signals emerged among responders, and high-grade TRAEs occurred at similar frequencies in both arms.
Clinical • P3 data • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • Sutent (sunitinib) • Cabometyx (cabozantinib tablet)
4d
NFE2L2 (NRF2 gene) knockdown was performed in tRCC cell lines (UOK146, FU-UR-1, UOK109) using a lentiviral doxycycline-inducible shRNA to assess the effects on cell proliferation...Conclusions tRCC tumors were found to have a low mutational burden, but still harbor recurrent genomic alterations such as 9p21.3 deletions, which are enriched compared to other forms of RCC. The transcriptional profile of tRCC was found to be characterized by activation of antioxidant stress response and NRF2 signaling, which may account for the resistance of these tumors to targeted therapies relative to ICIs.
Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TFE3
|
CDKN2A deletion • TMB-L • TFE3 fusion
|
doxycycline
4d
Key eligibility criteria: ≥ 18 years, histologically confirmed metastatic ccRCC, and progression after 1st line therapy. Enrollment began December 2020.
Clinical • P1/2 data • Combination therapy
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • GAS6 (Growth arrest specific 6)
|
AXL overexpression • HIF1A expression
|
Cabometyx (cabozantinib tablet) • batiraxcept (AVB-500)
4d
Secondary end points are progression-free survival, duration of response, and clinical benefit rate per RECIST v1.1 by blinded independent central review, overall survival, pharmacokinetics, and safety. The study will enroll patients in at least 9 countries (Australia, Belgium, Greece, Ireland, Israel, Netherlands, Russia, the United Kingdom, and the United States) and is recruiting.
Clinical • P2 data
|
EPAS1 (Endothelial PAS domain protein 1)
|
Welireg (belzutifan)
4d
Secondary endpoints include progression-free survival, best overall response, and safety. The study is currently open to enrollment.
Clinical • P2 data • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • BAP1 (BRCA1 Associated Protein 1) • CDK12 (Cyclin dependent kinase 12) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L)
|
Lynparza (olaparib)
4d
Median time to response was shorter and responses were more durable with NIVO+CABO versus SUN. No new safety signals emerged among responders, and high-grade TRAEs occurred at similar frequencies in both arms.
Clinical • P3 data • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Opdivo (nivolumab) • Sutent (sunitinib) • Cabometyx (cabozantinib tablet)
5d
P1b, N=50, Recruiting, NeoTX Therapeutics Ltd. | Trial completion date: Feb 2022 --> Jul 2022 | Trial primary completion date: Nov 2021 --> Apr 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
|
HER-2 negative • TPBG positive
|
Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
5d
Gemcitabine plus doxorubicin was well tolerated and demonstrated clinical activity in patients with platinum-refractory RMC, with a subset of patients experiencing durable responses lasting longer than 6 months. Further investigation is warranted to determine biomarkers of sensitivity and target mechanisms of resistance.
Clinical • Journal
|
SMARCB1
|
gemcitabine • doxorubicin hydrochloride
5d
PNET remains a pathological diagnosis and IHC has important place in diagnosis of PNET. Locally advanced and metastatic disease is common at diagnosis leading to overall poor survival.
Retrospective data • Review • Journal
|
FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
6d
Radical hepatectomy is the first choice for treatment of UESL. Intraoperative tumor rupture should be avoided and implant metastasis is a major factor affecting the prognosis of UESL.
Clinical • Journal
|
MUC16 (Mucin 16, Cell Surface Associated) • VIM (Vimentin)
|
VIM expression
6d
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • P4HB (Prolyl 4-Hydroxylase Subunit Beta)
6d
We found out different miRNA-mRNA regulatory networks of obesity-related ccRCC for both VAT and SAT; and several DE RNAs of obesity-related ccRCC were found to remain consistent performance in terms of ccRCC prognosis. Our findings could provide valuable evidence on the targeted therapy of obesity-related ccRCC.
Journal
|
CDH2 (Cadherin 2) • MIR182 (MicroRNA 182) • MIR425 (MicroRNA 425)
6d
Thus, embryonic hypoxia may explain this novel signature across multiple normal tissues. Our study suggests that hypoxic condition in an early stage of embryonic development is a crucial factor inducing C>T transitions at GpCpN sites; and individuals' genetic background may also influence their postzygotic mutation profiles.
Clinical • Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit)
7d
The knockdown of SHARPIN effectively inhibited acquired sorafenib resistance in ccRCC cell lines and tumor growth in xenograft models. In conclusion, our work reveals a novel post-translational regulation of SHARPIN on pVHL, indicating that SHARPIN may be a potential target for ccRCC treatment.
Journal
|
EPAS1 (Endothelial PAS domain protein 1)
|
Nexavar (sorafenib)
7d
Treatment with anti-IL-6 (αIL-6) antibody similarly reduced cell proliferation and migration and reduced renal tumors in Tsc2 mice while reducing PSAT1 expression. These data reveal a mechanism through which IL-6 regulates serine biosynthesis, with potential relevance to the therapy of tumors with mTORC1 hyperactivity.
Journal
|
IL6 (Interleukin 6) • TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
|
IL6 expression
7d
The novel nomogram optimized via RiskScore exhibited a promising predictive ability. It may be able to serve as a visualized tool for guiding clinical decisions and selecting effective individualized treatments.
Clinical • Observational data • Retrospective data • Journal
|
ETS1 (ETS Proto-Oncogene 1) • PAI1 (Plasminogen Activator Inhibitor 1)
7d
We also explored few interesting correlations between CTHRC1 expression and promoter methylation, genetic alterations, CNVs, CD8+ T immune cells infiltration, and tumor purity. In conclusion, CTHRC1 can serve as a shared diagnostic and prognostic biomarker in HNSC, KIRC, LIHC, LUAD, STAD, and UCEC patients of different clinicopathological features.
Journal
|
CD8 (cluster of differentiation 8)
7d
Our results suggest that tumors might drive the development of PD-L1-expressing NK cells that acquire immunoregulatory functions in humans. Hence, rational manipulation of these regulatory cells emerges as a possibility that may lead to improved anti-tumor immunity in cancer patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IL18 (Interleukin 18) • NKG2D (killer cell lectin like receptor K1)
|
PD-L1 expression • PD-L1-H
7d
We established a new Riskscore model for the prognosis of ccRCC based on metabolism. The genes in the model provided several novel targets for the study of ccRCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1)
7d
Moreover, TR4 mice showed a lower grade of histopathology than the control group. In conclusion, these results indicate that TR4 plays a key role in bladder cancer proliferation, and targeting TR4 would probably be a potential strategy for bladder cancer treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NR2C2 (Nuclear Receptor Subfamily 2 Group C Member 2)
|
BCL2 expression
7d
This pancancer analysis provided a comprehensive overview of the carcinogenic effects of GRWD1 on a variety of human cancers. The results of bioinformatics analysis indicated GRWD1 as a promising biomarker for detection, prognosis, and therapeutic assessment of diverse types of cancer, and GRWD1 could act as a tumor suppressor in KIRC.
Clinical • Journal • Tumor Mutational Burden • Pan tumor
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
7d
This study provides novel insights into the TME of rare kidney cancer types, which are often understudied. Our findings of differences in marker expression and localization by histological subtype could have implications for tumor progression and response to immunotherapies or other targeted therapies.
Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • CD68 (CD68 Molecule)
8d
P1, N=12, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Sep 2023
Trial completion date • IO biomarker
|
FGFR2 (Fibroblast growth factor receptor 2)
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin)
8d
Based on our findings, SGLT1 and nuclear EGFR overexpression defines a subgroup of CCRCC patients with good prognosis. Membranous-cytoplasmic EGFR expression was shown to be a poor prognostic factor and could define a CCRCC subgroup with poor prognosis that should be responsive to anti-EGFR therapies.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR overexpression
8d
The AXL/GAS6 scoring system could predict the outcome of prognosis and work as a robust biomarker for the immunogenomic state in RCC.
Journal
|
AXL (AXL Receptor Tyrosine Kinase) • GAS6 (Growth arrest specific 6)
|
Cabometyx (cabozantinib tablet)
8d
A high-risk score may represent an immunosuppressive microenvironment, while the high-risk group exhibited poor sensitivity to drugs. Our findings strongly indicate that the IFN-γ response-related signature can be used as an effective prognostic indicator of ccRCC.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • NUP93 (Nucleoporin 93)
8d
Gene knockdown of SMURF2 increased basal expression of HIF-1α even in the presence of Ro3306 or two different CDK4/6 inhibitors, palbociclib and abemaciclib...Proteasome inhibitor MG-132 partially rescued HIF-1α expression when Smurf2 was overexpressed...Overexpression of SMURF2 mRNA is correlated with improved disease-free survival and overall survival in clear cell renal cell cancer. Our results unravel a previously unknown mechanism involving Smurf2 for HIF-1α destabilization in CDK4/6 inhibitor-treated cells, thereby shedding light on VHL-independent HIF-1α regulation.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • CDK1 (Cyclin-dependent kinase 1)
|
HIF1A expression
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • MG132
8d
The extent of pseudoacinar and Golgi-like vascular architectural patterns was significantly different between CCRCC and ccpRCC (p < 0.05). Pathologists acquainted with these different vascular architectural patterns may utilize them as an additional tool in the distinction of CCRCC from ccpRCC.
Journal
|
CD34 (CD34 molecule)
8d
Notably, as a secreted phosphoprotein, STC2 was detectable in serum and possessed promising predictive value in several malignancies. This review aims to improve the understanding of the role of STC2 in patient diagnosis and prognosis, and tumor development and progression, as well as the mechanisms involved.
Journal
|
STC2 (Stanniocalcin 2)
9d
Up to 16 doses vaccine, combined with adjuvant GM-CSF and Imiquimod will be administered over 33 weeks. Tumor response will be assessed by RECIST. Systemic immune response to each neoepitope will be evaluated by FACS.
Combination therapy
|
CSF2 (Colony stimulating factor 2)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Zyclara (imiquimod)
9d
Clinical • Enrollment open • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
lenvatinib • Baize’an (tislelizumab)
9d
Sappanol and sventenin are safe and reliable compounds to target and inhibit MMP9. Sappanol can CCRCC cell migration and proliferation. These two compounds may give new thought to the targeted therapy for patients with CCRCC.
Journal
|
MMP9 (Matrix metallopeptidase 9)
9d
CONCLUSIONS We conclude that a downregulation of miR-184, miR-194-5p, and miR-203a expression is observed in both regressive and blastemal tumors, but larger-scale studies are needed to confirm whether the degree of their underexpression correlates with the number of blastemal elements in a sample. In most of our FFPE samples aged up to 9 years, RNA extraction provided miRNA with quantity and quality sufficient for qRT-PCR-based analysis, emphasizing the relevance of pathological archives as miRNA sources in future studies.
Journal • Polymerase Chain Reaction
|
MIR184 (MicroRNA 184) • MIR128 (MicroRNA 128) • MIR203A (MicroRNA 203a)
9d
The patient is currently being followed-up due to residual small liver adenomas. In our opinion, liver adenomatosis and renal cancer have the same cause in this case (chronic toxic effect of androgens).
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CA9 (Carbonic anhydrase 9)
9d
All SMARCB1-deficient carcinomas have a poor prognosis in common. Therefore, exact diagnosis of these tumors is a prerequisite for studies investigating new therapies.
Review • Journal
|
SMARCB1
9d
Our studies show that pharmacologic inhibition of TGF-β restores the expression of TCA cycle enzymes and suppresses tumor growth in an orthotopic model of RCC. Taken together, this investigation reveals a novel role for the TGF-β/HDAC7 axis in global suppression of TCA cycle enzymes in RCC and provides new insight into the molecular basis of altered mitochondrial metabolism in this malignancy.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
10d
P2, N=730, Completed, UNICANCER | Active, not recruiting --> Completed | Trial completion date: Jan 2023 --> Jun 2021
Clinical • Trial completion • Trial completion date
|
IL2 (Interleukin 2) • IFNA1 (Interferon Alpha 1)
|
Opdivo (nivolumab)
10d
Clinical • New P1 trial • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
|
KRAS mutation • TMB-H • MSI-H/dMMR • NRAS mutation
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • fludarabine IV • FT538
10d
FH deficiency has multiple oncogenic mechanisms including through promotion of aerobic glycolysis, induction of pseudohypoxia, post-translational protein modification and impairment of DNA damage repair by homologous recombination. FH-deficient neoplasms can present with characteristic morphological features that raise suspicion for FH alterations and also frequently demonstrate loss of FH immunoreactivity and intracellular accumulation of 2-succinocysteine, also detected by immunohistochemistry.
Review • Journal
|
FH (Fumarate Hydratase)
10d
Finally, exogenous ascorbic acid, a TET-activating demethylating agent, led to reversal of the above oncogenic effects of succinate in ccRCC cells. Collectively, our study demonstrates that functional SDH deficiency is a common adverse feature of ccRCC and not just limited to the kidney cancers associated with germline SDH mutations.
Journal
|
SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • MIR210 (MicroRNA 210) • SDHD (Succinate Dehydrogenase Complex Subunit D)
10d
Data of clinical researches demonstrating the association of KIM-1 with viral diseases and immune disorders have also been analyzed. Potential application of KIM-1 as urinary or serological marker in renal and cardiovascular diseases has been considered.
Review • Journal
|
KIM1 (Kidney injury molecule 1)
10d
The relationship to histologically similar tumor entities are presented and therapeutic options based on the genetic classification are discussed.
Journal
|
TSC2 (TSC complex subunit 2)
|
TSC2 mutation
10d
In this study, our data revealed the crucial TIICs and potential immune-related biomarkers for pRCC and provided compelling insights into the pathogenesis and potential therapeutic targets for pRCC.
Journal • IO biomarker
|
TOP2A (DNA topoisomerase 2-alpha) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55)
10d
In this model, high TIL-CD8 sig score was corresponding to a higher incidence frequency of copy number variation and drug sensitivity to sorafenib. Moreover, the prognosis of patients with the same or similar immune checkpoint gene levels could be distinguished from each other by TIL-CD8 sig score.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8)
|
CD8 expression
|
Nexavar (sorafenib)
11d
Other surveillance included 67 colonoscopies, 64 endoscopies, 65 breast MRI, 269 full blood evaluations and 39 FOBT with 8 new malignancies detected. The detection of 32 new primary cancers supports further evaluation of WBMRI in multi-organ cancer predisposition.
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • BAP1 (BRCA1 Associated Protein 1)
11d
Clinical • Enrollment change • Trial termination
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Viracept (nelfinavir)
12d
P1, N=152, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
PD-L1 expression • MET expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
12d
High tumoral expression of AXL was associated with inferior response to anti-PD-1 therapy and increased tumoral PD-L1 expression in patients with metastatic renal cell carcinoma, with particularly poor outcomes in those with high AXL and PD-L1. AXL expression has potential as a biomarker and therapeutic target.
Journal • PD(L)-1 Biomarker • IO biomarker
|
AXL (AXL Receptor Tyrosine Kinase)
|
PD-L1 expression • AXL expression
12d
The present study detected the role of FKBP51 in clear cell renal cell carcinoma (ccRCC), the most common subtype of RCC, and found that FKBP51 significantly promotes ccRCC invasion and migration by binding with the TIMP3, connecting TIMP3 with Beclin1 complex and increasing autophagic degradation of TIMP3. Given the important roles that TIMPs/MMPs play in ECM regulation and remodeling, our findings will provide new perspective for future investigation of the regulation of metastasis of kidney cancer and other types of cancer.
Journal
|
FKBP5 (FKBP Prolyl Isomerase 5) • BECN1 (Beclin 1)
13d
The Gene Set Enrichment Analysis suggested that ribosome, proteasome, inhibition of p53 signaling pathway, extracellular matrix receptor interaction, and homologous recombination were differentially enriched in increased PYCR1 mRNA phenotype.Increased PYCR1 mRNA is a potential marker in patients with AK. More importantly, p53 pathway, ribosome, proteasome, extracellular matrix receptor interaction, and homologous are differentially enriched in AK patients with increased PYCR1 mRNA.
Journal
|
PRO-C3 (Pyrroline-5-carboxylate reductase)
13d
We concluded PFKFB4 was associated with PPP activity and the fine-tuning of which was mediated by its phosphorylation of NCOA3. Targeting PFKFB4 held promise to combat resistance to Sunitinib.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • NCOA3 (Nuclear Receptor Coactivator 3)
|
HIF1A expression
|
Sutent (sunitinib)
13d
Lycorine induced the expression of 5-HETE, 12-HETE, 15-HETE and MDA in RCC cells, and reduced the GSH/GSSG ratio. In addition, ferrostatin-1 could prevent lycorine-induced ferroptosis in RCC cells.
Journal
|
GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4)
|
GPX4 expression
13d
RCC progression is regulated via the miR-501-3p/WTAP/CDK2 axis and is inhibited by the overexpression of miR-501-3p.
Journal
|
WT1 (WT1 Transcription Factor)
13d
The study constructed two nomograms suited for PRCC prognosis predicting. Moreover, we concluded that H19-miR-29c-3p-COL1A1 axis might promote the polarization of M2 macrophages and inhibit M1 macrophage activation through Wnt signaling pathway, collaborating to promote PRCC tumorigenesis and lead to poor overall survival of PRCC patients.
Journal
|
CD4 (CD4 Molecule) • COL1A1 (Collagen, type I, alpha 1)
14d
However, with innovation in ICIs and the creation of mutant IL-2 conjugates, there has been a drive for combination therapy. Knowledge of the HDIL-2 therapy and HDIL-2 related adverse events with radiology relevance is critical in diagnostic image interpretation.
Journal • Adverse events • IO biomarker
|
CD8 (cluster of differentiation 8)
14d
A field poorly analyzed in this neoplasia is the status of cell signaling pathways sensible to the redox state, which have been associated with the development and maintenance of RCC. This review focuses on alterations reported in the following redox-sensitive molecules and signaling pathways in RCC: mitogen-activated protein kinases, protein kinase B (AKT)/tuberous sclerosis complex 2/mammalian target of rapamycin C1, AKT/glycogen synthase kinase 3/β-catenin, nuclear factor κB/inhibitor of κB/epidermal growth factor receptor, and protein kinase Cζ/cut-like homeodomain protein/factor inhibiting hypoxia-inducible factor (HIF)/HIF as potential targets for redox therapy.
Review • Journal
|
EGFR (Epidermal growth factor receptor)
14d
Comprehensive understanding of both pathways informed and enabled mitigation of a major process risk: a sudden product decomposition. Detailed knowledge of the processes occurring during the reaction and their potential liabilities enabled the development of a robust photochemical continuous flow process implemented for commercial manufacturing.
Journal
|
CA9 (Carbonic anhydrase 9)
|
Welireg (belzutifan)
14d
Among these novel interacting proteins are Histone acetyltransferase 1 (HAT1) and all subunits of the heptameric coat protein complex I (COPI) that is involved in vesicle formation and protein cargo binding and sorting. We validate that the HAT1 and COPI interactions occur at endogenous levels but find that this interaction with COPI is not mediated through the C-terminal KxKxx cargo sorting signals of the COPI complex.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BAP1 (BRCA1 Associated Protein 1) • HAT1 (Histone Acetyltransferase 1)
14d
TRM cell abundance and phenotypes varied among CC, SC, RCC, and BC. Further studies regarding the functional differences of TRM associated with various tumors are warranted.
Journal
|
CD8 (cluster of differentiation 8) • ITGAE (Integrin Subunit Alpha E)
|
CD8 expression
15d
P2, N=5, Completed, University of Wisconsin, Madison | Recruiting --> Completed | N=15 --> 5 | Trial completion date: Jan 2023 --> Jun 2021 | Trial primary completion date: Jan 2022 --> Jun 2021
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
FOLH1 (Folate hydrolase 1) • CD31 (Platelet and endothelial cell adhesion molecule 1) • ENG (Endoglin)
|
FOLH1 expression
15d
Hemangioblastomas are slow-growing, very vascularized tumors. The most frecuent location is the cerebellum, the mainstem or the spinal chord. They may occur sporadically or as part of VHL disease which also includes retineal angiomas, endolymphatic sac tumors, renal cell carcinoma, pheocromocytoma, pancreatic cysts and neuroendocrine tumors.
VHL (von Hippel-Lindau tumor suppressor)
15d
Hemangioblastomas are slow-growing, very vascularized tumors. The most frecuent location is the cerebellum, the mainstem or the spinal chord. They may occur sporadically or as part of VHL disease which also includes retineal angiomas, endolymphatic sac tumors, renal cell carcinoma, pheocromocytoma, pancreatic cysts and neuroendocrine tumors.
VHL (von Hippel-Lindau tumor suppressor)
15d
Hemangioblastomas are slow-growing, very vascularized tumors. The most frecuent location is the cerebellum, the mainstem or the spinal chord. They may occur sporadically or as part of VHL disease which also includes retineal angiomas, endolymphatic sac tumors, renal cell carcinoma, pheocromocytoma, pancreatic cysts and neuroendocrine tumors.
VHL (von Hippel-Lindau tumor suppressor)
15d
Hemangioblastomas are slow-growing, very vascularized tumors. The most frecuent location is the cerebellum, the mainstem or the spinal chord. They may occur sporadically or as part of VHL disease which also includes retineal angiomas, endolymphatic sac tumors, renal cell carcinoma, pheocromocytoma, pancreatic cysts and neuroendocrine tumors.
VHL (von Hippel-Lindau tumor suppressor)
15d
A paradigm shift to the immunosuppressive environment was more obvious in metastatic lesions; rather the infiltration of Foxp3 and Foxp3PD-1 Treg cells was more pronounced. With this multiplexed single-cell pathology technique, we revealed further insight into the immunobiological standing of RCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • FOXP3 (Forkhead Box P3)
15d
We present additional evidence of renal cell carcinoma in two individuals with CS in their early twenties, and propose a reassessment of the abdominal surveillance in patients with PHTS. We propose biannual screening for kidney cancer beginning at 20 years of age.
Journal
|
PTEN (Phosphatase and tensin homolog)
15d
The AUC for CRP was 0.77 (95% CI: 0.74-0.80). Elevated CRP, low albumin levels, and elevated GPSs were all associated to poor survival in patients with RCC, Only CRP remained independent in multivariate analysis.
Clinical • Journal
|
CRP (C-reactive protein)
|
Albumin-L
15d
Furthermore, we show that this process regulates cell exit from the mitotic checkpoint. Collectively, our data demonstrates an interplay between the Hsp90 chaperone and VHL degradation machinery in regulating mitosis.
Journal
|
CD14 • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
15d
This study evidenced that up-regulated miR-138-5p inhibits proliferation and invasion of KIRC cells involving the transcription of SIN3A and the following regulation of the Notch signaling pathway.
Journal
|
MIR138 (MicroRNA 138)
15d
Journal
|
EPAS1 (Endothelial PAS domain protein 1) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO)
16d
Clinical • Enrollment open • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
azacitidine • bintrafusp alfa (M7824)
16d
Examined results undoubtedly showed NNMT as having the capacity to promote cell proliferation, migration and invasiveness, as well as its potential participation in fundamental events highlighting cancer progression, metastasis and resistance to chemo- and radiotherapy. In the light of this evidence, it is reasonable to attribute to NNMT a promising role as a potential biomarker for the diagnosis and prognosis of urologic neoplasms, as well as a molecular target for effective anti-cancer treatment.
Review • Journal
|
NNMT (Nicotinamide N-Methyltransferase)
16d
Transgelin expression was silenced by CRISPR/Cas9 and RNA interference, and the cells with reduced transgelin level exhibited significantly slower proliferation. Our data indicate that transgelin is an essential protein supporting RCC cell proliferation, which could contribute to intrinsic sunitinib resistance.
Journal
|
TAGLN (Transgelin)
|
Sutent (sunitinib)
16d
This study could demonstrate nivolumab-dependent effects on PD1 expression and tumor infiltrating T-cells in TSC of ccRCC. This is in line with results from other scientific studies about changes in immune cell proliferation in peripheral blood in response to nivolumab. Thus, TSC of ccRCC could be a further step to personalized medicine in terms of testing the response of individual patients to nivolumab.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1)
|
PD-1 expression
|
Opdivo (nivolumab)
16d
The protein expressions of PI3K (p110α) and p-AKT were significantly downregulated, while P27, P21, p-p38, p-ERK, and p-JNK were upregulated following combined treatment. These results revealed that metformin potentiates the anticancer effect of everolimus on cervical cancer, and combination treatment with metformin and everolimus provides a novel therapeutic strategy for patients with cervical cancer.
Preclinical • Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
everolimus • metformin
16d
These advances were made possible by the improved understanding of the VHL-HIF pathway. In this review, we summarize the historical evolution of ccRCC treatments, with a focus on the involvement of the VHL-HIF pathway.
Review • Journal
|
VHL (von Hippel-Lindau tumor suppressor)
16d
To verify possible effects of the tumor suppressor p53 on resveratrol-induced cell death, we used wild type and p53-deleted or -mutated cell lines for every tested tumor entity. Applying viability and cytotoxicity assays, we demonstrated a differential, dose-dependent sensitivity towards cis- or trans-resveratrol among the respective tumor types.
Journal
|
TP53 (Tumor protein P53)
16d
BRCA2 increased gastric cancer with RR = 2.15 (1.98-2.33). The meta-analysis results can provide clinicians and relevant families with information regarding increased specific cancer risk in BRCA1 and BRCA2 mutation carriers.
Clinical • Retrospective data • Review • Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA1 mutation • BRCA2 mutation • BRCA1 mutation + BRCA2 mutation • BRCA mutation
16d
Precise subtyping of undifferentiated (urothelial versus RCC and the exact underlying RCC subtype) is best done by thorough sampling supplemented as necessary by immunohistochemistry (e.g. FH, SDHB, ALK) and/ or molecular studies. This review discusses the morphological and molecular genetic spectrum and the recent develoments on the topic of dedifferentiated and undifferentiated genitourinary carcinomas.
Review • Journal
|
ALK (Anaplastic lymphoma kinase) • PBRM1 (Polybromo 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • VIM (Vimentin)
|
VIM expression
16d
In the current exploratory analysis, SETD2 mutations were significant predictors of MFP among patients treated for localized ccRCC. Our findings support future studies evaluating genetic alterations in preoperative renal biopsy samples as potential predictors of treatment outcome.
Clinical • Journal
|
PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • VHL (von Hippel-Lindau tumor suppressor) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • KDM5C (Lysine Demethylase 5C)
|
VHL mutation • BAP1 mutation • PBRM1 mutation • SETD2 mutation
16d
Routinely measured laboratory tests can refine current prognostic models, facilitate comparisons across clinical trial cohorts, and match patients with specific systemic therapies.
Clinical • Journal
|
CRP (C-reactive protein)
16d
The histological phenotype based on the eosinophilic features, which are linked to major immunological mechanisms of ccRCC, was significantly correlated with therapeutic efficacy.
Journal • IO biomarker
|
PBRM1 (Polybromo 1)
|
EMT gene signature
16d
Moreover, these stimulatory effects of RHBDD1 overexpression on RCC progression and the EGFR/AKT signaling pathway were partly reversed by gefitinib, an EGFR inhibitor. In conclusion, the findings of the present study suggested that RHBDD1 may be a crucial regulator of RCC by modulating the EGFR/AKT signaling pathway. The present study may provide a theoretical basis and potential targets for RCC treatment.
Journal
|
CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9) • SNAI2 (Snail Family Transcriptional Repressor 2)
|
gefitinib
16d
Tivozanib showed good activity and favorable safety profile in a real-world cohort of unselected patients with mRCC. Predictive biomarkers of response to antiangiogenic therapy are urgently needed in order to identify RCC patients who could still receive a monotherapy with VEGFR inhibitors in the first line.
Clinical • Journal
|
KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1) • FLT4 (Fms-related tyrosine kinase 4)
|
Fotivda (tivozanib)
17d
P1/2, N=42, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2028
Clinical • Trial completion date • Trial primary completion date • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
azacitidine • bintrafusp alfa (M7824)
17d
P1, N=90, Recruiting, Y Biologics Inc. | Trial completion date: Sep 2022 --> May 2023
Clinical • Trial completion date
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
PD-L1 expression • TMB-H • MSI-H/dMMR • ALK translocation
|
YBL-006
17d
Clinical • New P1 trial • Combination therapy
|
IL2 (Interleukin 2)
|
sasanlimab (PF-06801591) • PF-07263689
17d
Cabozantinib is a promising drug for patients with advanced/metastatic cervical cancer where few therapeutics options are available after failure to platinum-based regimen metastatic CC. It appears challenging to assess the interest of Cabozantinib in this indication, taking into account the potential toxicity of the drug.
Clinical • P2 data • Journal
|
KDR (Kinase insert domain receptor) • AXL (AXL Receptor Tyrosine Kinase)
|
Avastin (bevacizumab) • Cabometyx (cabozantinib tablet)
17d
Neither membranous nor cytoplasmatic CXCR4 histoscore was found to be mortality predictor. Our data showed that CXCR7 could be considered as a valid prognostic marker regarding survival of RCC patients.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • ACKR3 (Atypical Chemokine Receptor 3)
|
CXCR4 expression
17d
VEGFR-TKI + ICI combinations improved PFS but not OS as first-line therapy for mRCC patients with favorable IMDC prognosis. Longer follow-up and further studies will increase the power of our analysis, suggesting the best first-line therapy for mRCC patients with favorable prognosis.
Clinical • Review • Journal • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
Sutent (sunitinib)
17d
Many clinical trials are exploring effective treatments for patients with MSS/pMMR CRC, and the combination of ICIs and drugs with different mechanisms is expected to improve the efficacy of MSS/pMMR CRC patients. In the future, attention should be paid to finding the potential therapeutic markers of ICIs and the drug resistance mechanism of ICIs, so as to break through the immune tolerance of MSS/pMMR CRC patients.
Journal • Checkpoint inhibition • MSi-H Biomarker • IO biomarker
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
17d
His symptoms improved after repeated intravenous methylprednisolone pulse therapy and oral prednisolone. As consciousness levels improved, we observed quadriplegia and peripheral neuropathy with antiganglioside antibodies, which led to a diagnosis of polyradiculoneuropathy. This is a rare case of a patient with overlapping meningoencephalitis and polyradiculo-neuropathy induced by ICIs.
Clinical • Journal • Combination therapy
|
IL6 (Interleukin 6)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • methylprednisolone sodium succinate
17d
PPI network and functional enrichment analyses revealed that MAP3K8 correlated with NFKBIZ, MIAT, PARP15, CHFR, MKNK1, and ERMN, which was mainly involved in I-kappaB kinase/NF-kappaB and toll-like receptor signaling pathways. MAP3K8 overexpression was correlated with damaged survival in ccRC and may play a crucial role in cancer-related inflammation via I-kappaB kinase/NF-kappaB and toll-like receptor signaling pathways.
Journal • PARP Biomarker • IO biomarker
|
IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8)
|
MAP3K8 overexpression
17d
Furthermore, 52 (5.9%) patients were identified to carry pathogenic or likely pathogenic germline mutations in 22 cancer predisposition genes. This is the first large-scale comprehensive genomic analysis for Chinese ccRCC patients, and these results might provide a better understanding of molecular features in Chinese ccRCC patients, which can lead to an improvement in the personalized treatment for these patients.
Journal • Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
|
PD-L1 expression • TP53 mutation • MSI-H/dMMR • VHL mutation • PBRM1 mutation
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
17d
In patients with multiple piloleiomyomas HLRCC must be ruled out as it is confirmed in a high proportion of cases. The probability of fumarate hydratase mutation is greater in multiple piloleiomyomas involving both the trunk and upper extremities in the same patient.
Clinical • Journal
|
FH (Fumarate Hydratase)
|
FH mutation
17d
Evaluation of biomarkers' feasibility, sample preparation and storage, biomarker validation, and the application of novel technologies may provide a solution that maximises the potential for a truly non-invasive biomarker in early RCC diagnostics.
Review • Journal
|
CA9 (Carbonic anhydrase 9) • AQP1 (Aquaporin 1) • LCN2 (Lipocalin-2) • PLIN2 (Perilipin)
17d
We identified differential fatty acid derivatives and their metabolic networks as crucial biomarkers from metabolic profiles of different ploidy cyprinid fish subjected to A. hydrophila infection. These results highlighted the comparative metabolic strategy of different ploidy cyprinid fish against bacterial infection.
Journal
|
MMP9 (Matrix metallopeptidase 9) • CAT (Catalase) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
18d
Clinical • Enrollment open • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR T790M negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Actemra SC (tocilizumab SC)
18d
New trial • Liquid biopsy
|
HER-2 (Human epidermal growth factor receptor 2)
|
GuardantREVEAL
19d
Trial suspension
|
PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1) • CDK4 (Cyclin-dependent kinase 4) • POLD1 (DNA Polymerase Delta 1) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • CHEK1 (Checkpoint kinase 1) • RAD50 (RAD50 Double Strand Break Repair Protein) • BARD1 (BRCA1 Associated RING Domain 1) • CDK2 (Cyclin-dependent kinase 2) • RAD52 (RAD52 Homolog DNA Repair Protein) • WRN (WRN RecQ Like Helicase) • BACH1 (BTB Domain And CNC Homolog 1) • FANCG (FA Complementation Group G) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • RPA1 (Replication Protein A1) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2)
|
BARD1 mutation • WRN mutation • RPA1 mutation
|
Zejula (niraparib)
19d
As such, accurate diagnosis of this low-grade pattern among FH-deficient RCCs is worthwhile not only due to its association with HLRCC and need of genetic counseling and surveillance, but also due to more favorable prognosis. Finally, increasing experience with the low-grade end of the morphologic spectrum of FH deficient RCC reiterates that not all tumors of this subtype of RCC have a uniformly aggressive outcome.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • FH (Fumarate Hydratase)
19d
We present a new instrument targeting pathologies with p-VHL/HIF altered function that impact the PD-L2 expression through the change in transcriptional, growth factors, and AKT/mTOR modulation.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • VHL (von Hippel-Lindau tumor suppressor) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
PD-L1 expression
20d
ESC RCC has unique histomorphological manifestations, CK20(+ ) and CK7(-) are helpful for its diagnosis, and it has common molecular karyotype changes, supporting it as a unique tumor entity. The overall prognosis of the patient is good.
Clinical • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • VIM (Vimentin) • MLANA (Melan-A) • KRT20 (Keratin 20) • MME (Membrane metallo-endopeptidase)
20d
These data demonstrate the application of CD70 CAR-T cell therapeutic strategies for RCC and the cross-talk between targeting DNA damage responses and antitumor CAR-T cell therapy. These findings provide insight into the mechanisms of PARPis in CAR-T cell therapy for RCC and suggest a promising adjuvant therapeutic strategy for CAR-T cell therapy in solid tumors.
Journal • CAR T-Cell Therapy
|
CD70
20d
Additionally, we found that IRF3 was remarkably associated with tumor-infiltrating immune cells (TIICs) and various immune-related genes. Herein, we identified IRF3 from the IRF gene family members, which could serve as promising prognostic marker and therapeutic target in ccRCC.
Journal
|
IRF3 (Interferon Regulatory Factor 3)
20d
This study describes the largest cohort of 91 SDHC patients worldwide. We confirm disease-affected SDHC variant cases develop isolated HNPGL disease in nearly 2/3 of patients, EAPGL and PCC in 1/3, with an increased risk of GIST and RCC. One fifth developed malignant disease, requiring comprehensive lifelong tumour screening and surveillance.
Clinical • Journal
|
SDHC (Succinate Dehydrogenase Complex Subunit C)
20d
So, to sum up, H1-pHMGB1/pB7H3 vaccine could achieve the desired anti-tumor effect by enhancing the response of tumor-specific functional CD8 T cell responses. H1 nanoparticle-based vaccines may have great potential and prospect in the treatment of primary solid tumors.
Journal
|
CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • HMGB1 (High Mobility Group Box 1)
21d
The patient tolerated the operation well and final histopathology showed high grade renal cell carcinoma. Here we describe and recount the patient’s anesthetic management and discuss the potential hemodynamic consequences of IVC tumor extension.
Clinical
|
MTHFR (Methylenetetrahydrofolate Reductase)
21d
Adding SAbR did not improve the response rate to HD-IL-2 in patients with mRCC in this study. Tissue analyses suggest a possible correlation between frameshift mutation load as well as tumor immune infiltrates and clinical outcomes.
P2 data • Journal • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
21d
C19orf10 could discriminate KIRC patients with high-risk from low-risk. Taken together, C19orf10 contributes to KIRC development via ZO-1 and PTEN/Akt signaling pathway and C19orf10 could serve as a potential diagnostic and prognostic candidate and therapeutic target of KIRC.
Clinical • Journal
|
TJP1 (Tight Junction Protein 1)
21d
Tumor Immune Dysfunction and Exclusion (TIDE) analysis indicated that the high expression of SERPINE1 might be related to tumor immune evasion in KIRC. In summary, the current study constructing the MMP25-AS1/hsa-miR-10a-5p/SERPINE1 ceRNA network might be a novel significant prognostic factor associated with the diagnosis and prognosis of KIRC.
Journal
|
CXCL13 (Chemokine (C-X-C motif) ligand 13) • PAI1 (Plasminogen Activator Inhibitor 1) • CCL4 (Chemokine (C-C motif) ligand 4)
21d
These findings suggest that the TBC1D3 family expression is correlated with prognosis and immune infiltrating levels. Therefore, the TBC1D3 family can be used as a biomarker for KIRC and a prognostic biomarker for determining the prognosis and immune infiltration levels in KIRC.
Journal
|
CD4 (CD4 Molecule)
21d
Inhibited β-catenin substantially mitigated FSTL3-mediated promoting functions in RCC. In short, FSTL3 functions as an oncogene in RCC by modulating the GSK-3β/β-catenin signaling pathway.
Journal
|
CDH1 (Cadherin 1) • TGFB1 (Transforming Growth Factor Beta 1) • SNAI2 (Snail Family Transcriptional Repressor 2)
22d
Therefore, we speculated that the overexpression of CYP2J2 prolonged the survival outcome of KIRC patients, which may be related to the change of tumor immune microenvironment. Moreover, all these new understandings of CYP2J2 may provide important value for the early diagnosis and new targeted drug therapy of KIRC.
Journal
|
CD8 (cluster of differentiation 8)
22d
Mice inoculated with A498 and OSRC-2 cells transfected with miR-101-3p mimics showed significantly smaller xenografts and weaker EZH2 expression levels than the control group. miR-101-3p inhibited RCC cell proliferation, migration, and invasion by targeting EZH2.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
22d
In silico analysis of potential ZNF target genes found that the largest group of target genes are involved in cellular metabolic processes, which incidentally are particularly impaired in ccRCC. It was concluded from this study that gene expression of ZNF433 is associated with cancer progression and poorer prognosis, and that ZNF433 behaves in a manner that suggests that it is a prognostic marker and a possible tumor-suppressor gene in clear-cell renal cell carcinoma.
Journal
|
mTOR (Mechanistic target of rapamycin kinase) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • KDM5C (Lysine Demethylase 5C)
|
BAP1 mutation • PBRM1 mutation • MTOR mutation • SETD2 mutation
22d
Clinically relevant tumors with complete or almost complete absence of MUC5AC staining included small cell carcinoma of the lung (0% of 17), clear cell renal cell carcinoma (0% of 507), papillary thyroid carcinoma (0% of 359), breast cancer (2% of 1097), prostate cancer (2% of 228), soft tissue tumors (0.1% of 968), and hematological neoplasias (0% of 111). The highly standardized analysis of a broad range of cancers identified a ranking order of tumors according to their relative prevalence of MUC5AC expression.
Journal
|
MUC5AC (Mucin 5AC)
|
MUC5AC expression
22d
This blockage was accompanied by decreased cyclin E and Cdk2 levels and increased p21 level. Combination of metformin with irinotecan may be an effective treatment strategy for targeting colorectal cancer that are resistant to irinotecan monotherapy.
Preclinical • Journal
|
CDK2 (Cyclin-dependent kinase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
irinotecan • metformin
22d
Neoadjuvant studies such as NeoSun can safely and effectively explore translational biological and imaging endpoints.
P2 data • Journal
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • VEGFC (Vascular Endothelial Growth Factor C)
|
Sutent (sunitinib)
22d
ESC-RCC needs to be distinguished from a variety of eosinophilic RCC types with secondary cystic changes including cystic SDH-deficient RCC, the recently proposed eosinophilic vacuolated tumor (EVT; also mTOR-related), oncocytoma, and low-grade oncocytic tumor (LOT). The generally indolent behavior and frequent TSC/mTOR alterations in ESC-RCC, EVT, and some LOTs raise the question of whether these lesions represent independent tumor entities or are merely morphological variants on the spectrum of eosinophilic low-grade TSC/mTOR-related neoplasms.
Review • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TSC1 (TSC complex subunit 1)
|
TSC1 mutation
22d
Furthermore, its administration curbed cystogenesis in Pkd2 zebrafish and early-onset Pkd1-deficient mouse models. In conclusion, NS398 is a potential therapeutic agent for ADPKD.
Preclinical • Journal
|
PRKD1 (Protein Kinase D1)
22d
Re-introduction of PBRM1, or depletion of opposing corepressors using siRNA or drugs, redress coregulator imbalance and release RCC cells to terminal epithelial fates. These mechanisms thus explain RCC resemblance to the proximal tubule lineage but with suppression of the late-epithelial program that normally terminates lineage-precursor proliferation.
Journal
|
PBRM1 (Polybromo 1) • PAX8 (Paired box 8)
23d
Klotho may play a role as a biomarker for cancer surveillance in KTRs.
Clinical
|
KL (Klotho)
23d
Moreover, we found that E2F2 was a direct target of miR-214-5p, and lncRNA RCAT1 could protect E2F2 from miR-214-5p-mediated degradation. Taken together, our findings suggested that lncRNA RCAT1 could enhance the malignant phenotype of renal cell carcinoma cells by modulating miR-214-5p/E2F2 axis, and lncRNA RCAT1 might be a novel prognostic biomarker and a potential therapeutic target for renal cell carcinoma.
Journal
|
E2F2 (E2F Transcription Factor 2) • MIR214 (MicroRNA 214)
23d
We further show that only a subset of tumor cells dies by ferroptosis upon sulfasalazine and erastin treatment, implying that certain cell lines appear to be resistant to system x inhibition, while others undergo ferroptosis-independent cell death. From these findings, we conclude that sorafenib does not qualify as a bona fide ferroptosis inducer and that ferroptosis induced by system x inhibitors can only be achieved in a fraction of tumor cell lines despite robust expression of SLC7A11, the substrate-specific subunit of system x.
Preclinical • Journal
|
SLC7A11 (Solute Carrier Family 7 Member 11)
|
SLC7A11 expression
|
Nexavar (sorafenib) • erastin • sulfasalazine
24d
P1, N=234, Recruiting, Xencor, Inc. | Trial completion date: Mar 2025 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Jul 2023
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative
|
Yervoy (ipilimumab) • izuralimab (XmAb23104)
24d
P2, N=121, Active, not recruiting, Incyte Corporation | Trial completion date: Apr 2022 --> Jul 2022
Trial completion date
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • PD-L1 overexpression
|
retifanlimab (INCMGA0012)
24d
P1, N=48, Recruiting, AO GENERIUM | Trial completion date: Nov 2024 --> Jun 2024 | Trial primary completion date: Nov 2024 --> Apr 2024
Clinical • Trial completion date • Trial primary completion date
|
PD-1 (Programmed cell death 1)
|
GNR-051
24d
The functional experiments revealed that overexpression of ENTPD3-AS1 inhibited cell proliferation in RCC cell lines and the effect could be rescued by knocking down HIF-1α. Our findings reveal that SNP-mediated lncRNA-ENTPD3-AS1 upregulation suppresses renal cell carcinoma via miR-155/HIF-1α signaling.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • MIR155 (MicroRNA 155)
|
HIF1A expression
24d
In line with the aggressive nature, the high angiogenesis/stroma/proliferation cluster exclusively consists of tumors with ASPSCR1-TFE3 fusion. Here, we describe the genomic and transcriptomic features of TFE3-tRCC and provide insights into precision medicine for this disease.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TFE3
|
PD-L1 expression • TFE3 translocation • TFE3 fusion
24d
High-risk patients tended to have high cytolytic activity scores and immunophenoscore of CTLA4 and PD1/PD-L1/PD-L2 blocker than low-risk patients, suggesting these patients may be more suitable for immunotherapy. Therefore, our signature could provide clinicians with prognosis predictions and help guide treatment for ccRCC patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L2 (Programmed Cell Death 1 Ligand 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
24d
Compared with OPN, RLPN is more worthy of promotion and application, because it has better treatment outcomes, significantly reduces intraoperative blood loss, alleviates the body stress response and postoperative pain, and improves the quality of life.
Clinical • Clinical data • Journal
|
CRP (C-reactive protein)
24d
Supporting its distinction from related entities, gene expression analyses showed that LOT clustered separately from classic chRCC, chRCC-eo, and RO. In summary, converging mTORC1 pathway mutations, mTORC1 complex activation, and a distinctive gene expression signature along with characteristic phenotypic features support LOT designation as a distinct entity with both syndromic and non-syndromic cases associated with an indolent course.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TSC1 (TSC complex subunit 1) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • PAX8 (Paired box 8) • RHEB (Ras Homolog, MTORC1 Binding)
|
TSC1 mutation • MTOR mutation • PAX8 positive
24d
Knockdown of CHFR in ccRCC cells inhibited cell proliferation, colony formation, and migration ability. In summary, our findings suggest that the epigenetic signature on CHFR gene is a novel prognostic feature; furthermore, our findings offer theoretical support for the study of metastasis-related genes in ccRCC and provided new insights for the clinical treatment of the disease.
Journal
|
CHFR (Checkpoint With Forkhead And Ring Finger Domains)
24d
This study delineated the fibrosis-based tumor microenvironment characteristics of ccRCC. PRL/PRLR may be involved in the fibrosis process and are essential prognostic risk factors for ccRCC.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • COL1A1 (Collagen, type I, alpha 1) • PRLR (Prolactin Receptor 2)
24d
Our study provides novel insights into the role of NEDD4L in pan-cancer. NEDD4L may play a tumor suppressor effect in ccRCC, through tumor immune regulation and ubiquitination of key intracellular kinases.
Journal • Pan tumor
|
ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
24d
Our data suggest that the overexpression of TFEB promotes BCL-2 expression by upregulating its promoter activity and ultimately results in the development of t(6;11) translocation RCC. BCL-2 inhibitors may serve as potential therapeutic targets for t(6;11) translocation RCC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TFEB (Transcription Factor EB 2)
|
BCL2 expression • BCL2 translocation
24d
Patients benefit overall survival from enhanced CIK therapy in our clinical study. Our present preclinical and clinical studies for the first time elucidated that these enhanced CIK cells would be used as an effective adjuvant therapy in the treatment of RCC.
Preclinical • Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • GZMB (Granzyme B)
24d
More studies are needed to test the possibility of using PAX8 as a possible target for managing endometrial carcinomas. In this article, we review the functions of the PAX8 gene, how its mutations lead to the development of certain epithelial carcinomas, how it can be used as a diagnostic or a prognostic marker, and its potential as a therapeutic target for these cancers.
Review • Journal
|
PAX8 (Paired box 8)
24d
Overall, the present study demonstrated that Plin2 is involved in AKI; knockdown of this marker might limit apoptosis via the activation of PPARα. Consequently, the downregulation of Plin2 could be a novel therapeutic strategy for AKI.
Journal
|
PLIN2 (Perilipin) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
|
PLIN2 expression
24d
A high correlation was found between the concentrations of uKIM-1 and urine creatinine in three healthy subjects followed up for 3 weeks (Spearman's correlation coefficients were 0.758, 0.825 and 0.933, respectively). The data obtained are clear evidence of the need for normalization uKIM-1 to urine creatinine in RCC patients.
Clinical • Journal
|
KIM1 (Kidney injury molecule 1)
25d
Moreover, BAPCs isolated from tumor-draining lymph nodes of cancer patients showed increased percentages of tumor antigen-specific B cells and induced a strong response of autologous T cells in vitro. Our results highlight the relevance of BAPCs as professional antigen-presenting cells in tumor immunity and provide a mechanistic rationale for the recently observed correlation of B cell abundance and response to immune checkpoint inhibition.
IO biomarker
|
CD86 (CD86 Molecule)
26d
P1b/2, N=261, Completed, Pharmacyclics LLC. | Active, not recruiting --> Completed | Trial completion date: Nov 2021 --> Aug 2021 | Trial primary completion date: Nov 2021 --> Aug 2021
Clinical • Trial completion • Trial completion date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
EGFR expression
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • ibrutinib • paclitaxel • everolimus • docetaxel
26d
Since the patient BRAF-V600 is mutated, adjuvant therapy with the BRAF / MEK inhibitors dabrafenib 150 mg 1-0-1 and trametinib 2 mg 1-0-0 was initiated in November 2019, which in November 2020 after 1 year of adjuvant ended...therapy with nivolumab 480 mg iv every 4 weeks was initiated...therapy with nivolumab 480 mg iv every 4 weeks was initiated... If multiple neoplasms occur in young patients, Cowden's syndrome (germ cell mutation in the tumor suppressor gene PTEN) should be considered. The diagnosis is made on the basis of a combination of major (e.g. medullary thyroid cancer, endometrial cancer) and minor criteria (e.g.
PD(L)-1 Biomarker
|
PTEN (Phosphatase and tensin homolog)
|
BRAF mutation • BRAF V600 • PTEN mutation • PTEN-H
|
Opdivo (nivolumab) • Mekinist (trametinib) • Tafinlar (dabrafenib)
26d
The therapy was switched to a combined immunotherapy with ipilimumab and nivolumab. This brilliant course and the lack of therapeutic response are consistent with published data. It is easy to imagine
PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
26d
At the time of her first presentation, she had been receiving injections of bevacizumab every 4 weeks for 3 months...If the BAP1 tumor predisposition syndrome is present, the patient must be given genetic advice and receive appropriate preventive and follow-up care from a specialist. Since a choroidal melanoma with BAP1 mutation is particularly aggressive, further imaging follow-up can be discussed in the first few years of diagnosis.
BAP1 (BRCA1 Associated Protein 1)
|
BAP1 mutation
|
Avastin (bevacizumab)
26d
Finally, a nomogram integrating the model and clinical factors for clinical application showed a more robust predictive performance for prognosis. The prediction model associated with PBRM1 mutation status and immunity can serve as a promising tool to stratify patients depending upon their immune status, thus facilitating immunotherapy in the future.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PBRM1 (Polybromo 1) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
PBRM1 mutation
27d
In summary, the ARG signature could be a promising biomarker for monitoring the outcomes of WT. We established a novel nomogram based on the ARG signature, which accurately predicts the overall survival of WT patients.
Clinical • Journal • Gene Signature
|
HER-2 (Human epidermal growth factor receptor 2) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
27d
Mesothelioma (MESO) has the second highest alterations but has no therapy targets. This study provided a great and detailed interpretation of MEK1 expression, alterations and clinical implications in 32 types of cancer and reminded us to fill the gap in MEK1 research from a new perspective.
Clinical • Journal • Pan tumor
|
MAP2K1 (Mitogen-activated protein kinase kinase 1)
|
MAP2K1 expression
27d
On gray-scale US, MA appears as a solid nodule with a well-defined boundary, regular morphology, and homogeneous echogenicity; CEUS shows slow progression and slightly lower homogeneous enhancement and fast wash-out in the medullary phase. These findings may provide insight into the progression of MA and aid in the development of diagnostic and therapeutic strategies.
Clinical • Journal
|
WT1 (WT1 Transcription Factor) • VIM (Vimentin) • MME (Membrane metallo-endopeptidase)
|
WT1 positive
27d
Therefore, our studies delineated the oncogenic role of CDC20 and its prognostic significance at the pan-cancer level and proved its functional activity in Cdc20 high expression cancer types. Our studies will merits further molecular assays to understand the potential role of Cdc20 in tumorigenesis and provide the rationale for developing novel therapeutic strategies.
Journal • Pan tumor
|
PLK1 (Polo Like Kinase 1) • CCNA2 (Cyclin A2) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
|
CDC20 overexpression
27d
These proteins may be recognized as new biomarkers for RCC. These findings could broaden our insight into the underlying molecular mechanisms of RCC and identify candidate biomarkers for the treatment of RCC.
Clinical • Journal • PARP Biomarker
|
CD14 • PARP1 (Poly(ADP-Ribose) Polymerase 1) • SOD2 (Superoxide Dismutase 2)
27d
Altogether, our data argue to consider LOT as a distinct entity with a favorable clinical outcome. However, in case of metastasis, an accurate diagnosis of LOT would be essential for the patient's management and could allow targeted therapy.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TSC1 (TSC complex subunit 1) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
|
TSC1 mutation • MTOR mutation
27d
Moreover, CCL5 and FASLG expression may be related to the formation of the immunosuppressive microenvironment in the tumors of patients with KIRP. In conclusion, the immune microenvironment landscape presented in this study provides a novel insight for further experimental and clinical exploration of tailored immunotherapy for patients with KIRP.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • FASLG (Fas ligand)
27d
In addition, high PARP1 expression was positively associated with microsatellite instability event in COAD, KIRP, BRCA, glioblastoma multiforme (GBM), lung squamous cell carcinoma (LUSC), LGG, READ, UCEC, SKCM and LUAD (P < 0.05). Our results highlight the significance of PARP1 alterations as pan-cancer predictive biomarkers for ICI treatment, and its expression levels seem to be correlated with the status of immunotherapy-associated signatures, thus may be a promising biomarker for predicting ICI response in several tumors.
Journal • Tumor Mutational Burden • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker • Pan tumor
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • TMB-H • LAG3 expression • CTLA4 expression • PARP1 overexpression
27d
Our results indicate that TLR3 serves as a prognostic biomarker and associated with immune infiltration in KIRC. This work lays a foundation for further studies on the role of TLR3 in the carcinogenesis and progression of KIRC.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • TLR7 (Toll Like Receptor 7) • TLR3 (Toll Like Receptor 3)
27d
In addition, mRNA expression of E2F1/2/3/4/7/8 was positively correlated with infiltration of six types of immune cells, including B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells. These results indicate that E2F1/2/3/4/7/8 may be used as a prognostic marker for the survival of ccRCC patients and laid the foundation for studying the immune infiltration role of E2Fs family members in tumors.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • E2F1 (E2F transcription factor 1) • E2F5 (E2F Transcription Factor 5)
27d
Clinical samples confirmed that TNFSF13B expression was significantly associated with DFS but not with OS. TNFSF13B may be a potential prognostic molecular marker of poor survival in ACC patients, offering a new therapeutic target.
Journal
|
TNFSF13B (TNF Superfamily Member 13b)
27d
Multivariate analyses showed that high p-CREB1staining was an independent risk factor for cancer-specific free survival, overall survival and progression-free survival. p-CREB1 protein is an independent prognostic biomarker for ccRCC patients.
Journal
|
CREB1 (CAMP Responsive Element Binding Protein 1)
27d
Current recommendations for management and surveillance of TSC are discussed as well. RSNA, 2021.
Journal
|
TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
|
TSC1 mutation • TSC2 mutation
28d
The keys to distinguish CCC on cytology are the proliferation of one type of epithelial cell with squamous differentiation, solid pattern, low-grade cytology, minimal atypia, vacuolated or clear cytoplasm, absence of myoepithelial or prominent mucinous differentiation, lack of mucinous stroma and obvious keratinization, and the support of a panel of immunohistochemical stains. Fewer than 10 cytology cases of CCC have been reported in literature.
Clinical • Review
|
TP63 (Tumor protein 63)
28d
Additional molecular analysis is ongoing. Close follow-up is recommended.
ALK (Anaplastic lymphoma kinase) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • CCND1 (Cyclin D1) • ETV6 (ETS Variant Transcription Factor 6) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • EWSR1 (EWS RNA Binding Protein 1) • TFE3 • FH (Fumarate Hydratase) • PAX8 (Paired box 8) • TFEB (Transcription Factor EB 2) • CTSK (Cathepsin K) • MME (Membrane metallo-endopeptidase)
|
NTRK1 fusion • NTRK2 fusion • CCND1 expression • PAX8 positive
|
Archer® FusionPlex® Oncology Research Kit
28d
Based on histologic appearance and p40 expression the tumor was diagnosed as thymoma, World Health Organization type B3. This presentation emphasizes the role of judicious use of immunohistochemistry in arriving at a definitive diagnosis in the context of malignancy with clear cell and ambiguous histopathologic features, despite a high index of suspicion for metastatic cancer.
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD5 (CD5 Molecule) • CA9 (Carbonic anhydrase 9) • PAX8 (Paired box 8)
28d
SV40, a marker frequently used for BKV infection, showed positive nuclear staining (Figure 1.131, D), however, BKV RNA in situ hybridization was negative. Expression of BKV antigen was identified in tumor cells with no evidence of BKV RNA, raising a possible connection between CDC tumorigenesis and history of longtime BKV infection.
PAX8 (Paired box 8) • GATA3 (GATA binding protein 3)
28d
However, she developed extensive deep vein thrombosis and pulmonary embolism and died 4 months after the diagnosis. Because of the extremely aggressive clinical course, careful histologic examination and a panel of immunohistochemistry are required to render the correct diagnosis.
SMARCB1 • TFE3 • PAX8 (Paired box 8) • TP63 (Tumor protein 63) • CTSK (Cathepsin K) • GATA3 (GATA binding protein 3)
|
PAX8 positive
28d
The differential diagnosis for this entity includes mucinous tubular and spindle cell carcinoma, metanephric adenoma, clear cell RCC, and urothelial carcinoma. Awareness of these emerging entities, which may be included in the next WHO classification, is essential to prevent misdiagnosis.
Clinical
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CCND1 (Cyclin D1) • TFE3 • PAX8 (Paired box 8) • TFEB (Transcription Factor EB 2) • CTSK (Cathepsin K)
|
CCND1 expression • PAX8 positive
28d
Additionally, many of the capillaries in the tumor were filled with sickled red blood cells (Figure 1.108, D). This case illustrates an unusual atypical oncocytic tumor that has not been described in a patient with sickle cell trait.
ALK (Anaplastic lymphoma kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CA9 (Carbonic anhydrase 9) • VIM (Vimentin)
|
ALK positive
28d
A select immunohistochemistry panel (CK7, CD117, vimentin) can identify malignancies and classic oncocytoma that would otherwise receive an uncertain diagnosis. In addition, our study helps to recognize an emerging entity, LOT of kidney.
Clinical
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CA9 (Carbonic anhydrase 9) • VIM (Vimentin)
28d
Furthermore, it may spur investigation among other recipients of organs from the same donor. Awareness of this largely nonpreventable complication and prompt implementation of molecular testing if cancer transmission is suspected are critical for proper management of these patients.
Clinical
|
NKX2-1 (NK2 Homeobox 1)
28d
Differential diagnoses include leiomyoma and leiomyosarcoma, gastrointestinal stromal tumor, melanoma, and metastatic renal cell carcinoma. Careful evaluation of clinical, histologic, and immunohistochemical findings should facilitate an accurate diagnosis.
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule)
29d
P3, N=1046, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2022 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
Clinical • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet)
29d
Our findings suggest that combining photodynamic therapy with sunitinib represents a minimally invasive therapeutic procedure with cancer selectivity for renal cell carcinoma.
Journal
|
CASP3 (Caspase 3)
|
PAI1 expression
|
Sutent (sunitinib)
29d
HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5)
29d
Microsatellite instability and copy number variations were not found in any of the 17 analyzable cases. EVT represents an emerging renal entity that shows a characteristic and readily identifiable morphology, consistent immunohistochemical profile, indolent behavior, and mutations in either TSC1, TSC2, or MTOR genes.
Clinical • Journal • Next-generation sequencing
|
MSI (Microsatellite instability) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • mTOR (Mechanistic target of rapamycin kinase) • TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • TFE3 • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • VIM (Vimentin) • MLANA (Melan-A) • PAX8 (Paired box 8) • CTSK (Cathepsin K) • MME (Membrane metallo-endopeptidase)
|
TSC1 mutation • MTOR mutation • TSC2 mutation
29d
A number of studies have indicated that ferroptosis is closely associated with acute renal failure, tumor, ischemia and reperfusion injury, neurodegenerative diseases and liver fibrosis. Liver fibrosis, which has long been a global health problem, still lacks effective treatment till now, and the discovery of ferroptosis provides a new insight into addressing this issue.
Review • Journal
|
GPX4 (Glutathione Peroxidase 4)
29d
This work revealed that a histone modifier gene inactive mutation reprogramed glycogen metabolism and helped to explain the long-standing puzzle of male predominance in human cancer. In addition, our findings may suggest the therapeutic value of targeting glycogen metabolism in ccRCC.
Journal
|
VHL (von Hippel-Lindau tumor suppressor) • KDM5C (Lysine Demethylase 5C)
|
VHL mutation • KDM5C mutation
1m
Therefore, these results indicated that CS-pL-Myc/pCAIX vaccine could effectively induce CD8 DCs and CD103 DCs mediated tumor-specific multi-functional CD8 T cell responses and exert the anti-tumor efficacy. This vaccine strategy offers a potential and promising approach for solid or metastatic tumor treatment.
Journal
|
CD8 (cluster of differentiation 8) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • CA9 (Carbonic anhydrase 9) • ITGAE (Integrin Subunit Alpha E)
1m
Our results indicated that PVT1 promotes ccRCC cells proliferation by sponging miR-328-3p to upregulate FAM193B and activate the MAPK/ERK and PI3K/AKT pathways. Collectively, these results suggest that PVT1- miR-328-3p-FAM193B loop could serve as a potential biomarker and therapeutic target for ccRCC.
Journal
|
AGO2 (Argonaute RISC Catalytic Component 2) • MIR328 (MicroRNA 328) • PVT1 (Pvt1 Oncogene)
1m
In conclusion, the significantly increased plasma EV PD-L1 in WT patients contributed to the immunosuppression of peripheral CD8 T cells. Monitoring the level of plasma EV PD-L1 will be helpful for the selection of immune-targeted therapies for WT patients.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD69 (CD69 Molecule)
1m
Reverting KLF2 expression in vivo decreased pulmonary metastatic lesions and prolonged life span of mice, whereas GPX4 overexpression reversed these properties. Overall, our results established a novel critical pathway that drives human ccRCC invasion and metastasis, which could be a promising target regarding to the therapies of advanced ccRCC in the clinic.
Journal
|
GPX4 (Glutathione Peroxidase 4)
|
GPX4 expression • GPX4 overexpression
1m
Moreover, CD40-CD40L interaction induced a cytoskeleton reorganization and increased the expression of integrin β1 on RCC cell lines, and this effect was reversed by cyclosporine A and NFAT inhibition. These data suggest that CD40 ligation induces the activation of different intracellular signaling pathways, in particular the NFATs factors, that could represent a potential therapeutic target in the setting of patients with metastatic RCC.
Journal • IO biomarker
|
CD40 (CD40 Molecule) • CD40LG (CD40 ligand) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
|
cyclosporin A microemulsion
1m
p53 may be involved in sunitinib resistance and represent a valuable marker for sunitinib treatment in mRCC.
Retrospective data • Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 expression
|
Sutent (sunitinib) • Nutlin-3
1m
In addition to VHL inactivation, promoter methylation of APC may be a universal pathognomonic event in the tumorigenesis of RCC and a candidate diagnostic and therapeutic biomarker.
Journal
|
VHL (von Hippel-Lindau tumor suppressor) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • APC (APC Regulator Of WNT Signaling Pathway) • CASP8 (Caspase 8) • DAPK1 (Death Associated Protein Kinase 1) • KLLN (Killin P53 Regulated DNA Replication Inhibitor)
|
VHL mutation
1m
CVB exerted anti-ccRCC effects by blocking the IGFBP3-AKT/STAT3/MAPK-Snail pathway. Targeted inhibition of IGFBP3 with CVB treatment may become a promising therapeutic regimen for ccRCC.
Journal
|
IGFBP3 (Insulin-like growth factor binding protein 3)
1m
Somatic variants characteristics may distinguish ccpRCC from ccRCC or pRCC and germline VAFAs may be a molecular characterization of ccpRCC. Compared with ccRCC or pRCC, ccpRCC patients may be significantly correlated with higher risk of developing second primary malignancy.
Journal
|
FANCA (FA Complementation Group A) • FANCI (FA Complementation Group I)
|
FANCA mutation • FANCI mutation
1m
In addition, we identified multiple miRNA, kinase, and transcription factor targets of YTHDF2 in KIRC and constructed target networks. Overall, our findings show that YTHDF2 is a possible indicator of immune infiltration in the KIRC.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
1m
Despite the abundance of correlative studies, the relationship between CRP levels and genitourinary cancer pathogenesis is not clearly understood. Here, we review the evidence for CRP as a biomarker in genitourinary (GU) cancers, with specific focus on potential clinical applications.
Review • Journal
|
CRP (C-reactive protein)
1m
With multivariate Cox regression, only baseline fibrinogen level (p = 0.001) was identified as an independent risk factor for progression-free survival; meanwhile, fibrinogen level (p = 0.048) and distant metastasis (p = 0.043) were identified as independent risk factors for survival. Overall, relatively high CRP/Alb ratios, fibrinogen, and distant metastasis were associated with a poor prognosis of Xp11.2 tRCC adult patients; among them, only baseline fibrinogen levels independently predicted the progression of Xp11.2 tRCC; thus, it may help to identify patients with worse progression or death risk.
Clinical • Journal
|
CRP (C-reactive protein)
1m
Autophagy degrades aging organelles and long-lived proteins and produces nutrients for cell recycling. To the best of our knowledge, the present review is the first to summarize the research that has been conducted on autophagy-regulated PD-L1 expression, which may provide new avenues for tumour immunotherapy.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression
1m
To sum up, our study partially demonstrated that the novel ZNF263/circFOXP1/miR-423-5p/U2AF2 axis has a role in RCC progression. Our results might provide a new direction for RCC therapeutic target exploring.
Journal
|
FOXP1 • ZNF263 (Zinc finger protein 263)
1m
LOT exhibits characteristic low grade oncocytic morphology with a CD117 negative/CK7 positive immunophenotype. Herein, we describe two cases of this emerging entity, LOT, with emphasis on the diagnostic aspects, including the histomorphology, immunoprofile and discussion on the close differentials.
Clinical • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
1m
In conclusion, the findings of the present study suggested that FOXO3a may inhibit nephroblastoma cell proliferation, migration and invasion, while inducing apoptosis, by downregulating the Wnt/β‑catenin signaling pathway. These results may provide a novel method for the early diagnosis and precise treatment of nephroblastoma.
Journal
|
CCND1 (Cyclin D1) • FOXO3 (Forkhead box O3)
|
CCND1 expression
1m
TP53 and BRAF v600E had aberrant immunostaining. Chromosomal microarray and genomic sequencing revealed loss of chromosome 10 p15.3-p11.2 and both somatic and germline DICER1 mutations, consistent with recent research and further supporting the classification of this tumor within the DICER1 syndrome associated tumors.
Journal
|
BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • DICER1 (Dicer 1 Ribonuclease III)
|
BRAF V600E
1m
A heterozygous pathogenic variant was detected in the FH gene. : To our knowledge, this is the first case possibly linking HL and T-ALL through FH deficiency.
Journal
|
FH (Fumarate Hydratase)
|
FH mutation
1m
Therefore, hsa_circ_0002024 was identified as a prognostic ceRNA that might sponge hsa_miR_129-5p to regulate ASF1B and affect RCC prognosis. However, further validation is needed.
Journal
|
FOXM1 (Forkhead Box M1)
1m
Moreover, ARAP1-AS1 sponges miR-361-3p to increase PGF expression. In conclusion, our study revealed that ARAP1-AS1 enhanced the malignancy of ccRCC cells by regulating the miR-361-3p/PGF axis.
Journal
|
MIR361 (MicroRNA 361)
1m
Clinical • Trial completion • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • simlukafusp alfa (RG7461)
1m
P2, N=50, Recruiting, Universitätsmedizin Mannheim | Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Sep 2021 --> Dec 2021
Clinical • Trial completion date • Trial primary completion date
|
VEGFA (Vascular endothelial growth factor A) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
1m
Consistent with inhibition of Hoxb9 expression by WT1, both transcripts are distributed in an almost non-overlapping pattern in embryonic mouse kidneys. Regulation of HOXB9 expression by WT1 might become relevant during kidney development and cancer progression.
Journal
|
WT1 (WT1 Transcription Factor)
1m
We showed that tumor tissue BAI1 expression level is a prognostic marker in ccRCC. Therefore, this gene might be involved in a prognostic panel to improve scoring systems on which the management of metastatic ccRCC patients is based.
Journal
|
FGF4 (Fibroblast growth factor 4) • EPHB2 (EPH Receptor B2) • PDGFB (Platelet Derived Growth Factor Subunit B)
1m
The immunotherapy target PD-L1 was consistently up-regulated in resistant cells, and we demonstrated that the silencing of this gene resulted in an increase in sensitivity to sunitinib treatment only in 786-O-resistant cells, suggesting that some ccRCC patients might benefit from combination therapy with PD-L1 checkpoint inhibitors. In summary, we demonstrate that, although there are clearly divergent mechanisms of sunitinib resistance in ccRCC subtypes, the commonality of miRNAs in multiple pathways could be targeted to overcome sunitinib resistance.
Journal
|
MIR17 (MicroRNA 17)
|
Sutent (sunitinib)
1m
PLK1 inhibitor BI2356 inhibits the growth of xenografts formed by ACHN OIP5 cells. Collectively, the OIP5 network can be explored for personalized therapies in management of pRCC patients.
Journal
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
1m
P53 silencing did not affect the ability of PTEN knockdown to induce apoptosis in cervical cancer cells. Taken together, the present study results imply that PTEN silencing induces apoptosis and decreases proliferation in cervical cancer cells; hence, PTEN inhibition may represent a promising strategy for the treatment of cervical cancer.
Journal
|
PTEN (Phosphatase and tensin homolog) • CCND1 (Cyclin D1) • CASP3 (Caspase 3) • CCNA2 (Cyclin A2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
1m
The results showed null associations between plasma homocysteine levels and overall BRCA (effect = 0.97, 95% CI: 0.90-1.06, P = 0.543), overall PrCa (effect = 1.01, 95% CI: 0.93-1.11, P = 0.774), RCC in men (effect = 0.99, 95% CI: 0.73-1.34, P = 0.929), and RCC in women (effect = 0.89, 95% CI: 0.61-1.31, P = 0.563). We found no putative causal associations between homocysteine and risk of BRCA, PrCa, and RCC.
Journal • BRCA Biomarker
|
BRCA (Breast cancer early onset)
1m
There is overlap between pulmonary metastatic tumor and primary tumor in morphology. Therefore, the diagnosis should be made by combining clinical history, pathological morphology and immunophenotypic characteristics.
Clinical • Journal
|
NKX2-1 (NK2 Homeobox 1) • CDX-2 • VIM (Vimentin) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • MME (Membrane metallo-endopeptidase)
1m
These findings suggest that XDH is a valuable prognostic biomarker in HCC and other cancers and indicate that it may function in tumor immunology. Loss of XDH expression may be an immune evasion mechanism for HCC.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8)
1m
In vivo experiments confirmed that SNHG17 promoted the growth of RCC tumors. SNHG17/miR-328-3p/H2AXaxis might be involved in RCC progression, which provided a potential therapeutic target for RCC.
Journal
|
MIR328 (MicroRNA 328)
1m
ZC3H13 might shape a noninflamed phenotype in KIRC. Moreover, ZC3H13 could predict the prognosis and clinical response of ICB and the sensitivity to targeted therapies in KIRC.
Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden)
1m
Pathway enrichment analysis discovered that 9 lncRNAs held potential roles in cell division, cell cycle, DNA damage and cytokines levels in RCC. This work indicates that the established 9-lncRNA signature has a good capacity in predicting the prognosis of RCC patients with stage IV and histological grade of G4, and may be helpful for guiding the treatment strategies for RCC patients.
Clinical • Journal
|
NUTM2A (NUT Family Member 2A) • LINC01559 (Long Intergenic Non-Protein Coding RNA 1559)
1m
Follow-up includes a magnetic resonance imaging abdomen with and without contrast, chest X-ray, and laboratories (basic metabolic panel, complete blood count, and C-reactive protein) 6 months postablation. Overall, percutaneous microwave ablation is an effective and safe treatment option for renal cell carcinoma in both T1a and T1b tumors in selected patients with multiple studies showing excellent oncologic outcomes when compared with partial and radical nephrectomy.
Journal
|
CRP (C-reactive protein)
1m
The transcription factor c-Myc may promote the expression of PRR11 in ccRCC cells by binding to the PRR11 promoter region, thereby accelerating the progression of ccRCC. In summary, we found that PRR11 could serve as a novel oncogene in ccRCC, and PRR11 could reduce the protein stability of E2F1 and could be activated by c-Myc.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • E2F1 (E2F transcription factor 1)
|
MYC expression
1m
CHEK2 mutations were not associated with any change in bladder or kidney cancer survival regardless of their age, sex, smoking status and family history. We observed a potentially protective effect of CHEK2 mutations on survival for patients with stage T1 bladder cancer. CHEK2 missense mutations were more common among patients with low grade invasive bladder cancer and in patients with stage Ta diease. The frequencies of the I157T CHEK2 pathogenic variant were less in patients with high grade invasive bladder cancer and those with stage T1 disease. Among patients with bladder cancer with stage Ta disease, the OR for any mutation in CHEK2 was 2.0 but for those with stage T1 disease, the OR was 0.3. We observed truncating CHEK2 mutations were associated with kidney cancer patients with GII clear cell carcinoma.
Clinical • Journal
|
CHEK2 (Checkpoint kinase 2)
|
CHEK2 mutation
1m
P=N/A, N=32, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2021 --> Mar 2023
Clinical • Trial completion date • Trial primary completion date
|
IL2 (Interleukin 2)
|
tremelimumab (CP-675206)
1m
Journal
|
AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
1m
Journal
|
AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
1m
We showed that global genome hypermethylation in VHL mutants can be explained by transcriptional changes in MDH and L2HGDH genes that cause the accumulation of 2-hydroxyglutarate - a metabolite that inhibits DNA demethylation by TET enzymes. Unlike the known cases of DNA hypermethylation in cancer, 2-hydroxyglutarate was accumulated in the cells with the wild-type isocitrate dehydrogenases.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • VHL (von Hippel-Lindau tumor suppressor)
|
VHL mutation
1m
P1, N=12, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Mar 2021 --> Jan 2022 | Trial primary completion date: Mar 2021 --> Oct 2021
Clinical • Trial completion date • Trial primary completion date • Combination therapy • Mismatch repair • IO biomarker
|
BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
PD-L1 expression • TMB-H • MSI-H/dMMR • BRAF mutation
|
Keytruda (pembrolizumab)
1m
P1/2, N=162, Recruiting, BeiGene | Trial completion date: Sep 2023 --> Jan 2024 | Trial primary completion date: Mar 2023 --> Jul 2023
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Baize’an (tislelizumab) • BGB-A425
1m
The performance of the nomogram was favorable (concordance index = 0.766) and reliably predicted the 3-year (AUC = 0.792) and 5-year (AUC = 0.766) survival of patients with KIRC. The novel six antioxidant related gene signature could effectively forecast the prognosis of patients with KIRC, supply insights into the interaction between cellular antioxidant mechanisms and cancer, and is an innovative tool for selecting potential patients and targets for immunotherapy.
Journal • Gene Signature • IO biomarker
|
GSTP1 (Glutathione S-transferase pi 1) • PRDX2 (Peroxiredoxin 2)
1m
Sophoricoside, aucubin, notoginsenoside R1 and ginsenoside Rg1 did not exhibit notable anti‑RCC activity, whereas the effect of ginsenoside Re and allicin on RCC was considerably weak. However, naringenin showed potent anti‑proliferative, apoptosis inducing and cell cycle arresting activity on RCC cells via regulation of the PTEN/PI3K/AKT signaling pathway.
Preclinical • Journal
|
PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • mTOR (Mechanistic target of rapamycin kinase) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CASP8 (Caspase 8)
|
PTEN expression • BCL2 expression
1m
SNU-333 cell line exhibited resistance via iron metabolism and stemness, and had tumor-initiating capacities in vitro and in vivo. These results suggest that among the cells tested, SNU-333 cells were the most promising for the establishment of an orthotopic RCC model for further researches.
Preclinical • Journal
|
GPX4 (Glutathione Peroxidase 4) • PAX8 (Paired box 8) • MME (Membrane metallo-endopeptidase)
1m
Our data indicated that exosomal miR-214-3p has potential as a novel biomarker of RTK.
Journal
|
MIR214 (MicroRNA 214)
1m
The missense mutation of TNS1 encoding the S1309Y mutation was found to be related to cell migration by gene over-expression. These findings suggest that macroscopically and microscopically heterogenous tumors might show heterogenous gene mutations and reactivity to TILs.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8)
1m
New trial • Checkpoint inhibition • IO biomarker
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
1m
Choriocarcinoma should be taken into consideration when associated symptoms and significantly elevated blood levels of β-hCG were identified.
Clinical • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • MME (Membrane metallo-endopeptidase)
1m
This article describes the main acquisitions of RCC management, including the advent of a new combo (pembrolizumab+lenvatinib) as first-line therapy, the confirmation of an OS advantage of ICI plus VEGFR-TKI combinations over sunitinib at longer follow-up, the persistent benefit from these combinations in particular subgroups (clear cell mRCC tumors with sarcomatoid differentiation), and possible new approaches in subsequent lines of therapy (including the HIF-2α inhibitor belzutifan). This 2021 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized management of mRCC.
Journal
|
EPAS1 (Endothelial PAS domain protein 1)
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • lenvatinib • Welireg (belzutifan)
1m
We demonstrate the utility of combining high-resolution MS and the TPA as potential new diagnostic tool in the pathology of renal neoplasms. A similar TPA approach may be implemented in any cancer study with solid biopsies.
Clinical • Journal
|
TUBB3 (Tubulin beta 3 class III) • PLIN2 (Perilipin) • LAMP1 (Lysosomal Associated Membrane Protein 1)
1m
Avelumab is an IgG1 anti-programmed death ligand 1 (anti-PD-L1) monoclonal antibody that has been approved as a monotherapy for metastatic Merkel cell carcinoma and advanced urothelial carcinoma, and in combination with axitinib for advanced renal cell carcinoma. Avelumab is cleared faster and has a shorter half-life than other anti-PD-L1 antibodies, such as atezolizumab and durvalumab, but the mechanisms underlying these differences are unknown...These studies suggest that the rapid internalization of avelumab might be due to simultaneous binding of both PD-L1 and FcγR in trans. Our findings also provide a basis to alter the clearance and half-life of monoclonal antibodies in therapeutic development.
Journal
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Inlyta (axitinib)
1m
Furthermore, the heterogeneity of plasma cells in ccRCC was also found to contribute to metastasis of the disease. This study offers potential novel therapeutic targets against distant metastasis of cancers, and can help to improve the therapeutic efficiency of ccRCC patients.
Journal
|
B2M (Beta-2-microglobulin)
1m
This results in an altered autophagic process and an increased proliferative capacity in renal cell lines. Our study suggests that NBR1 may be a new predisposing gene for RCC, however its characterization needs to be further investigated in order to confirm its role in renal carcinogenesis.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • SQSTM1 (Sequestosome 1) • FLCN (Folliculin)
|
BRCA1 mutation
1m
Hemangioblastomas are slow-growing, very vascularized tumors. The most frecuent location is the cerebellum, the mainstem or the spinal chord. They may occur sporadically or as part of VHL disease which also includes retineal angiomas, endolymphatic sac tumors, renal cell carcinoma, pheocromocytoma, pancreatic cysts and neuroendocrine tumors.
VHL (von Hippel-Lindau tumor suppressor)
1m
P1, N=152, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Clinical • Enrollment closed • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
PD-L1 expression • MET expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
1m
Women with HLRCC may be identified through the distinct clinical characteristics: symptomatic and numerous leioymyomas at young age, and morphologic features of FH-mutant leiomyomas, aided by Bcl-2 and CD34 immunohistochemistry. Further, distinguishing individuals with a germline FH mutation enables proper genetic counseling and regular renal monitoring.
Clinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD34 (CD34 molecule) • FH (Fumarate Hydratase)
1m
Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab)
1m
Positivity for PD-L1 expression by 73-10, as compared to 28-8, was associated with worse clinicopathological factors and prognosis for patients with RCC.
Journal • Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay • PD-L1 IHC 28-8 pharmDx • PD-L1 IHC 73-10 pharmDx
1m
The FK506-binding protein (FKBP) is a family of intracellular receptors that can bind specifically to the immunosuppressant FK506 and rapamycin...Cell Counting Kit 8 (CCK-8) and Transwell assays revealed that knockdown of FKBP10 and FKBP11 inhibits proliferation, migration, and invasion of the ccRCC cell line. FKBP10 and FKBP11 play important roles in ccRCC phenotypes and are potential prognostic markers as well as new therapeutic targets for patients with ccRCC.
Journal
|
mTOR (Mechanistic target of rapamycin kinase) • FKBP5 (FKBP Prolyl Isomerase 5)
|
sirolimus
1m
TZAP expression has a positive correlation with TRF1 and TRF2 in normal tissue but not in cancer. Our analyses indicate that TZAP has an important role in oncology and may be considered as a potential biomarker.
Journal
|
TERF1 (Telomeric Repeat Binding Factor 1) • TERF2 (Telomeric Repeat Binding Factor 2)
1m
We believe dermatologists should play a key role in the management of this side-effect. Therefore, we ought to be familiar with it in order to be able to identify and treat it appropriately without discontinuation of anticancer treatment.
Clinical • Journal
|
CD8 (cluster of differentiation 8) • MLANA (Melan-A)
|
Opdivo (nivolumab)
1m
Cabozantinib (CAB) is a receptor tyrosine kinase inhibitor with activity against MET, VEGFR2, and AXL, among others. In a phase-III study that examined the efficacy of combination therapy with CAB and nivolumab in treatment-naive patients with advanced renal cell carcinoma, progression-free survival was significantly increased in patients on combination therapy over patients on sunitinib monotherapy. Three global phase-III clinical studies of combination therapy with atezolizumab and CAB in patients with non-small cell lung cancer, castration-resistant prostate cancer, and renal cell carcinoma, are in progress to confirm the efficacy of CAB.
Clinical • Clinical data • Journal
|
KDR (Kinase insert domain receptor) • AXL (AXL Receptor Tyrosine Kinase)
|
Opdivo (nivolumab) • Tecentriq (atezolizumab) • Sutent (sunitinib) • Cabometyx (cabozantinib tablet)
1m
Based on qRT-PCR results, the NOP2 and NSUN4 mRNA expressions were higher and those of NSUN6 and TET2 were lower in ccRCC tissues than in normal tissues. Our results demonstrate that mC RNA methylation regulators may affect ccRCC progression and could be exploited for diagnostic and prognostic purposes.
Journal
|
TET2 (Tet Methylcytosine Dioxygenase 2)
1m
Our report illustrates the clinical utility of comprehensive genomic profiling in benefiting the diagnosis of MS, the selection of therapeutic strategy and the determination of whether MS is donor-derived.
Clinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • DNMT3A (DNA methyltransferase 1)
|
KRAS mutation • DNMT3A mutation
1m
Of note, it was found by western blot analysis that Bcl-2 protein expression was downregulated by the decreased protein stability of Bcl-2 in pioglitazone-treated Caki cells. In conclusion, these findings indicated that pioglitazone-induced apoptosis is regulated through caspase-mediated degradation of FLIP and reduction of Bcl-2 protein stability, suggesting that pioglitazone is a feasible apoptotic agent that could be used in the treatment of human RC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • FADD (Fas associated via death domain) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • CFLAR (CASP8 and FADD-like apoptosis regulator) • IL1B (Interleukin 1, beta)
|
BCL2 expression • CFLAR expression
|
pioglitazone
1m
This study shows that metastases in ccRCC patients are ten times as likely to be associated with high COX-2 immunoexpression than low COX-2 immunoexpression. COX-2 plays a role in the process of ccRCC metastasis without PD-L1 involvement.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
PD-L1 expression • PTGS2 expression
1m
Compound 6a was superior to reference drugs vorinostat and valproic acid in its ability to inhibit growth/proliferation of A-498 and Caki-1 renal cancer cells...Finally, the high potency and selectivity of 6a towards HDAC2 and FAK proteins were rationalized by molecular docking. Taken together, these findings highlight the potential of 6a as a promising dual-acting HDAC2/FAK inhibitor that could benefit from further optimization.
Journal
|
HDAC2 (Histone deacetylase 2)
|
Zolinza (vorinostat)
1m
We indicate that germline screening should be encouraged in early-onset patients. Clinicopathological data, such as family history and immunohistochemical results can provide valuable clinical information for the differential diagnosis of HLRCC-associated RCC in advance.
Clinical • Review • Journal
|
FH (Fumarate Hydratase)
1m
Therefore, TSC/mTOR/autophagy/Nurr1 signaling is partially responsible for the tumorigenesis of TSC. Taken together, Nurr1 may be a novel therapeutic target for TSC-associated tumors, and Nurr1 agonists or reagents that induce Nurr1 expression may be used for the treatment of TSC.
Journal
|
TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
|
TSC1 mutation • TSC2 mutation
1m
P2, N=4, Completed, Sunnybrook Health Sciences Centre | Recruiting --> Completed | N=35 --> 4 | Trial completion date: Dec 2021 --> Aug 2021 | Trial primary completion date: Dec 2021 --> Aug 2021
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab)
1m
P2, N=60, Recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022
Trial completion date • Trial primary completion date
|
SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
|
SETD2 mutation
|
FoundationOne® CDx
|
adavosertib (AZD1775)
1m
P1/2, N=82, Recruiting, Klus Pharma Inc. | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
A166
2ms
Taken together, our unpresented pan-cancer analysis of DLGAP5 provides a relatively integrative understanding of the oncogenic role of DLGAP5 in various tumors. DLGAP5 may prompt HCC cellular proliferation, invasion and metastasis. All of these provides solid basement and will promote more advanced understanding the role of DLGAP5 in tumorigenesis and development from the perspective of clinical tumor samples and cells.
Journal • Pan tumor
|
CD8 (cluster of differentiation 8)
2ms
Based on the results of a pivotal phase II trial in patients with NSCLC/pulmonary sarcomatoid carcinoma, savolitinib was recently granted approval in China (conditional on the results of a phase III trial) for the treatment of metastatic NSCLC with MET exon 14-skipping alterations in patients who have progressed after or who are unable to tolerate platinum-based chemotherapy. This article summarizes the milestones in the development of savolitinib leading to this first approval.
Review • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET exon 14 mutation
|
Orpathys (savolitinib)
2ms
Collectively, ferroptosis could be involved in the diverse and complex TME. Evaluation of the ferroptosis patterns may heighten the comprehension about immune infiltrations in the TME, assisting oncologists to generate individualized immunotherapeutic strategies.
Journal • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden)
2ms
Kyn could promote 786-O cells migration and invasion. Gut microbiota could activate AhR through its tryptophan metabolite Kyn to mediate RCC metastasis.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • AHR (Aryl hydrocarbon receptor)
|
CDH1 expression • AHR expression • VIM expression
2ms
Supportively, preclinical studies using RCC mouse xenografts demonstrated that combining sunitinib with the small molecule anti-estrogen PHTPP can increase sunitinib efficacy with reduced VM formation. Collectively, the findings of this study may aid in the development of potential biomarker(s) and novel therapies to better monitor and suppress RCC progression.
Journal
|
ER (Estrogen receptor)
|
Sutent (sunitinib)
2ms
Our findings underscore the importance of risk stratification and cardiovascular monitoring for patients on ICI therapy.
Clinical data • Journal • Adverse events • Checkpoint inhibition • Real-world evidence
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
2ms
P1, N=155, Recruiting, Pfizer | N=37 --> 155 | Trial completion date: Nov 2024 --> Dec 2023 | Trial primary completion date: Nov 2024 --> Dec 2023
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Inlyta (axitinib) • sasanlimab (PF-06801591) • PF-07265807
2ms
P=N/A, N=830, Completed, Chugai Pharmaceutical | Active, not recruiting --> Completed | N=600 --> 830 | Trial completion date: Dec 2019 --> Jul 2021 | Trial primary completion date: Dec 2019 --> Jul 2021
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
2ms
We report case of MTSCC of kidney pT3aN0 Grade 2 shares histologic and immunohistochemical overlap with papillary renal cell carcinoma (RCC negative with focal expression, CK7, EMA and AMACR high and moderate positive with prevalence in the tubular com- ponent without mucin, Vimentin totally positive and focally of NSE, CD10 and CK20 negative, Ki-67 proliferative index 0,9-2,8%) with a favourable 5-year progression free survival prognosis.
Clinical
|
VIM (Vimentin) • MME (Membrane metallo-endopeptidase)
2ms
WT in adults is extremely rare and has a poorer prognosis than paediatric WT. Histopathologically, there is no difference between adult and childhood WT. Due to the scarcity of cases in the literature, there are no standard protocols for the management of adult WT, and therefore, it is managed as paediatric WTs.
Clinical
|
WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • SYP (Synaptophysin)
2ms
We report this case to draw attention to this entity and notice that eosinophilic RCCs should be examined thoroughly for SDH- defi- ciency because of its highly syndromic nature.
Clinical
|
SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
2ms
Cystic renal neoplasm varies from benign to malignant. Cystic RCC is frequently misdiagnosed as a benign renal cyst because it shares similar clinical manifestations and imaging characteristics. Cystic presentation of ChRCC is believed to account for 4% of all mor- phological variants of chromophobe RCC.
KIT (KIT proto-oncogene, receptor tyrosine kinase) • MME (Membrane metallo-endopeptidase)
|
KIT positive
2ms
In conclusion, the primary osteogenic OS of the kidney is extremely rare. Up-to-date, only 28 cases have been reported, which characterize high local recurrence rate and distant metastatic potential. The differential diagnosis with sarcomatoid RCC requires extended sam- pling and immunohistochemical assessment.
CD34 (CD34 molecule)
2ms
Paediatric renal rhabdoid tumour is an uncommon and highly aggressive malignancy found in young children, diagnosed mainly during the first 2 years of life. Because of the advanced stage at the time of presentation, his early detection and diagnosis are critical to ensure proper therapeutic management. Our first patient, 6 years later was in complete remission of symptoms after chemotherapy treatment and the second one, 3 months fol- lowing diagnosis, responds well to chemoradiotherapy treatment.
Clinical • Review
|
VIM (Vimentin)
2ms
Coexistence of renal cell carcinoma and Non-Hodgkin B- cell lymphoma is what makes this case unique. Few similar cases were reported, one of which suggests that patients with non-Hodgkin lympho- ma have an increased risk for renal cell carcinoma. Therefore, we are looking forward to a future research which could prove the correlation between these two neoplasms or even identifying one as an etiological factor for the other.
Clinical
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • SOX11 (SRY-Box Transcription Factor 11)
|
CD20 expression • CCND1 expression